

Location, location, location

Buckley, Christopher; Ospelt, Caroline; Gay, Steffen; Midwood, Kim S

DOI:

[10.1038/s41584-020-00570-2](https://doi.org/10.1038/s41584-020-00570-2)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Buckley, C, Ospelt, C, Gay, S & Midwood, KS 2021, 'Location, location, location: how the tissue microenvironment affects inflammation in RA', *Nature Reviews Rheumatology*, vol. 17, no. 4, pp. 195-212. <https://doi.org/10.1038/s41584-020-00570-2>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is a post-peer-review, pre-copyedit version of an article published in *Nature Reviews Rheumatology*. The final authenticated version is available online at: <https://doi.org/10.1038/s41584-020-00570-2>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

***Nature Reviews* referee guidelines**

Review articles

Nature Reviews publishes timely, authoritative articles that are of broad interest and exceptional quality. Thank you for taking the time to help us to ensure that our articles meet these high standards.

Review articles in *Nature Reviews* journals provide accessible, authoritative and balanced overviews of a field or topic. These articles are targeted towards readers from advanced undergraduate level and upwards, including researchers, academics and clinicians, and should be accessible to readers working in any discipline.

Please submit your report in narrative form and provide detailed justifications for all statements. Confidential comments to the editor are welcome, but it is helpful if the main points are stated in the comments for transmission to the authors.

Please note that all *Nature Reviews* articles will be thoroughly edited before publication and all figures will be redrawn by our in-house art editors. We therefore request that you concentrate on the scientific content of the article, rather than any minor errors in language or grammar.

Please consider and comment on the following points when reviewing this manuscript:

- Is the article timely and does it provide a useful addition to the existing literature?
- Are the scope and aims of the article clear?
- Are the ideas logically presented and discussed?
- Is the article accessible to a wide audience, including readers who are not specialists in your own field?
- Does the article provide a balanced overview of the literature? Please bear in mind that it may not be possible to cover all aspects of a field within such a concise article.
- Does the article provide new insight into recent advances?
- Is the discussion fair and accurate? Although our authors are encouraged to be opinionated, they should not ignore alternative points of view.
- Do the figures, boxes and tables provide clear and accurate information? Are there any additional or alternative display items that you think that the authors should include?
- Are the references appropriate and up-to-date? Do they reflect the scope of the article?
- Are you aware of any undeclared conflicts of interest that might affect the balance, or perceived balance, of the article?

Location, location, location: understanding how the local tissue microenvironment drives inflammation in arthritis

Christopher D. Buckley^{1,2}, Caroline Ospelt³, Steffen Gay³ and Kim S. Midwood^{1}*

¹ Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.

² Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.

³ Department of Rheumatology, Center of Experimental Rheumatology, Zurich, Switzerland.

*e-mail: kim.midwood@kennedy.ox.ac.uk

Abstract

Current treatments for rheumatoid arthritis (RA) **do not work well for a large proportion of patients, they do not work at all in some people, nor can they cure or prevent this disease.** One major obstacle to developing better drugs is lack of a complete understanding of how inflammatory joint disease arises and progresses. Here, we discuss emerging evidence **as to** how the tissue microenvironment impacts RA pathogenesis. Each tissue is made up of cells surrounded and supported by a unique extracellular matrix. These complex molecular networks define tissue architecture and provide environmental signals that programme site-specific cell behaviour. In the synovium, a major site of disease activity in RA, both **positional**

26 and disease stage-specific cellular diversity exists. Improved resolution of the
27 architecture of the synovium, from gross anatomy to the single cell level, in parallel
28 with evidence demonstrating how the synovial extracellular matrix is vital for
29 synovial homeostasis, and how dysregulated signals from the matrix drive chronic
30 inflammation and tissue destruction in the RA joint, have opened up new ways to
31 think about RA pathogenesis, and offer novel therapeutic approaches for people
32 with hard to treat disease, or as a means of disease prevention.

33

34

35 **Introduction**

36 Tissue specialization is essential for life. However, the fundamental principles that
37 drive tissue-specific cell behaviour are not fully understood. For example, why are
38 fibroblasts in the gut so different to those in the skin, and why do macrophages
39 resident in the brain behave differently to those in the liver? Technologies that can
40 interrogate tissues at the single cell level are being used to generate an encyclopedic
41 inventory of the different cell populations comprising each tissue of the body,
42 revealing extraordinary levels of cellular complexity and phenotypic plasticity.

43 Mapping the anatomic location, and the interaction networks, of newly discovered
44 cell subsets will be the next essential step towards understanding tissue structure
45 and function. Moreover, cells do not exist in a vacuum. The tissue microenvironment
46 is a key determinant of cell behaviour, enabling cells to perform distinct roles
47 dictated by their **anatomical location, as well as specifically by their location within**
48 **tissues**. But what defines the microenvironment? Cells in tissues are surrounded
49 and supported by an extracellular matrix. In each tissue the matrix is made up of a
50 combination of more than 1000 different secreted molecules that is unique to that

51 tissue, assembled into a complex 3D network, providing external cues that govern
52 cell behaviour. Understanding how tissues function in health and disease therefore
53 requires knowing both the identity of resident cell populations and how complex
54 external microenvironments cohesively define cell phenotype in situ.

55

56 In this review we focus on the synovium, and examine how changes in both the
57 cellular and extracellular compartments of this tissue play a causal role in driving
58 chronic inflammation during rheumatoid arthritis (RA). We will review how recent
59 single-cell transcriptional analysis has revealed extraordinary microanatomical
60 complexity within the RA synovium, identifying at least 18 distinct cell phenotypes,
61 amongst which diverse subpopulations exhibit striking **positional** and functional
62 segregation. We discuss how these studies provide compelling new insights into the
63 cellular basis of inflammatory joint disease. We also highlight the evidence that
64 extracellular networks create anatomically distinct sub-synovial niches within which
65 environmental cues dictate **site-specific behaviour, that is behaviour that is unique**
66 **to the position of any cell within a tissue**. We detail how these networks directly
67 contribute to chronic inflammation in the inflamed joint, and we examine why this
68 information changes the way we think about how inflammatory joint disease arises
69 and progresses, offering new methods of patient stratification, as well as novel
70 classes of therapeutic drugs. Finally, we highlight the key questions and challenges
71 that remain.

72

73 **What exactly is the tissue microenvironment?**

74 All tissues consist of cells surrounded by an intricate extracellular matrix. This 3D
75 network of secreted molecules provides structural support for cells and dictates
76 their spatial organization within tissues. However, the matrix is not simply an inert
77 scaffold, it also a key determinant of cell phenotype, providing environmental cues
78 that enable cells to move relative to each other as well as perform distinct roles
79 determined by their anatomic location^{1,2}. Extracellular matrices are made from a
80 selection of more than 1000 molecules collectively called the matrisome. Genes in
81 the matrisome code for all of the proteins that can be secreted by cells,
82 encompassing extracellular matrix molecules, matrix-associated proteins, soluble
83 growth factors, chemokines and cytokines, and enzymes including proteases and
84 kinases³ (<http://matrisomeproject.mit.edu/>).
85
86 Expression of site-specific combinations of matrisome molecules, and their assembly
87 into networks around cells, creates unique tissue microenvironments, as well as local
88 niches within tissues. Integrated mechanical and biochemical cues from each type of
89 matrix provide essential context for cell behavior, wherein distinct combinations of
90 extracellular molecules cohesively define cell differentiation and specialization. For
91 example, joints are specialized multi-tissue organs that provide the structures by
92 which bones move relative to each other, and by which muscles mediate
93 coordinated locomotion. The components of a classical human synovial joint include
94 tissues such as the synovium, tendons, muscle, ligaments, bursae, menisci, articular
95 cartilage and subchondral bone. Each constituent tissue of the joint is made up of a
96 unique combination of matrisomal molecules that confer the distinctive physical
97 properties that together are essential for effective joint function (**Box 1**).

99 The extracellular matrix is as dynamic as it is complex, changing throughout
100 development and ageing, as well as during inflammation and disease. However, for
101 most human tissues, including the joint, we lack a detailed understanding of the
102 molecular and topological organization of the extracellular networks surrounding
103 cells. It is also not clear how tissue architecture changes during inflammation, nor
104 the functional implications of these changes. Here, we review emerging data that
105 highlight the importance of understanding the complex interplay between cells and
106 their matrix microenvironment in defining cell behaviour within the synovium, and
107 in controlling joint inflammation.

108

109 **Complex tissue architecture within the synovium**

110 The synovium is an intricate tissue, made up of a number of cell types including
111 tissue resident macrophages, fibroblasts, nerve and endothelial cells. Even at the
112 gross histological level, subcellular compartmentalization within the synovium is
113 evident forming two distinct zones; the intima lining layer and the subintima (**Box 1**).
114 In a healthy joint the intima is only 1-3 cells thick, and is composed of tissue resident
115 macrophages and fibroblasts supported by a porous basement-like membrane. This
116 zone of the synovium controls cellular and molecular ingress and egress between the
117 synovium and the joint cavity, playing a key role in maintaining joint integrity and the
118 composition of synovial fluid, ensuring effective joint lubrication and nutrient
119 exchange. The subintima, comprising fibroblasts distributed throughout a looser
120 collagenous extracellular matrix, and containing blood and lymphatic vessels, and

121 nerves serves to vascularise and enervate the synovium, and provide transport
122 routes for cells, nutrients and lymph into and out of synovial tissue⁴.
123
124 The synovium becomes markedly expanded in RA, with the intimal layer increasing
125 up to as much as 10-20 cells in thickness. Infiltrating immune cells join resident
126 macrophages and proliferating fibroblasts to cause synovial hyperplasia. This
127 **quantitative** change in the cellular ecosystem is accompanied by qualitative changes
128 in cell phenotype; expansion and activation of lymphocytic, myeloid and fibroblast
129 subpopulations that promote inflammation and tissue destruction, alongside
130 suppression of cell subsets that mediate the resolution of inflammation, occurs,
131 driving the immune status of the joint towards chronic inflammation^{5,6}.
132
133 Changes in the organization of the synovial architecture are also evident in RA. There
134 is not just vast and random cellular influx and expansion; **a specific selection of cells**
135 **only enter the joint, organized by the chemokine repertoire of the synovium.**
136 **Moreover** the tissue is markedly reorganized, creating new compartmentalized
137 niches within which pathogenic cell behaviour is confined^{5,6}. For example, ectopic
138 (or tertiary) lymphoid structures develop in the synovium during RA in around 40%
139 of patients, with around 10-25% of samples exhibiting germinal center-like
140 structures⁷. These aggregates of lymphocytes resemble secondary lymphoid organs,
141 albeit with varying degrees of organization, characterized by a T cell-rich zone
142 enclosing a central B cell-rich zone, served by a network of high endothelial venules
143 that enhances naïve T and B cell recruitment to the synovium (reviewed in ⁸). Biopsy
144 studies have shown the existence of gradients of CXCL13 and CCL19/CCL21 which

support cellular segregation, and where B cells differentiate in situ into plasma cells, supporting autoantibody production⁸. Lymphoid-rich synovitis, defined by a distinct transcriptomic profile, and by high serum CXCL13, represents a histologically distinct subset of patients with high disease activity, who are difficult to treat⁹. These data exemplify how disease pathotypes or endotypes can be categorized based on synovial cell ecosystems.

The pannus is also a well-described architectural feature of the inflamed synovium.

Although used historically, the term pannus is likely to be replaced with 'activated aggressive RA synovium'. This region of hypertrophic synovium, often called the aggressive front, is composed of macrophages and fibroblasts that release tissue degrading enzymes responsible for invasion of cartilage and bone⁶ (**Figure 1a**).

Most interestingly is the fact that RA synovial fibroblasts attach to the cartilage matrix and invade it progressively and destructively, a close relationship that has been observed in studies of the MLR/lpr mouse model¹⁰, as well as models using engraftment of human synovial tissue or isolated synovial fibroblasts together with human cartilage in SCID mice^{11,12}. These areas of invasive pannus formation have been well studied at the molecular level, revealing that this tissue niche is hypoxic¹³, and displays discrete patterns of gene expression. This encompasses upregulation of genes such as MMPs^{14,15}, TLRs¹⁶, p53^{17,18} and SUMO/Sentrin¹⁹, and down regulation of the tumor suppressor gene PTEN²⁰, which combine to create a destructive milieu in which aggressive pannus-resident cells are protected from apoptosis. Moreover, changes in epigenetic marks have been suggested to contribute to the aggressive phenotype of synovial fibroblasts at the site of invasion

into cartilage²¹. Expression of tissue degrading enzymes and apoptosis-inhibiting factors in RA synovial fibroblasts found at the sites of cartilage destruction is associated with gene hypomethylation; and this altered epigenetic landscape might explain why therapeutically targeting the progression of RA joint destruction is extremely difficult²². Some studies have also reported how the tissue microenvironment itself changes within the pannus, and the consequences of altered extracellular protein expression on localized tissue invasion. For example, galectin-3, a secreted beta-galactoside-binding protein that is elevated early in RA pathogenesis, localizes almost exclusively to the pannus in the inflamed synovium (**Figure 1b**)^{23,24}. Galectin-3 directly activates synovial fibroblasts, stimulating secretion of inflammatory cytokines, such as interleukin-6 (IL-6), and chemokines, such as IL-8, CCL2, CCL3, and CCL5, as well as MMP3, via activation of MAPK and phosphatidylinositol 3-kinase (PI 3-kinase) signalling pathways²⁵. Moreover, galectin-3 expression by RA synovial fibroblasts is required for IL6 synthesis downstream of TLR2²⁶, a pattern recognition receptor that also localizes to the pannus in inflamed synovia (**Figure 1c**)¹⁶. Together these data imply that local interplay between galectin-3 and TLR2 serves to activate pannus-resident synovial fibroblasts, in a cytokine-independent manner, and recruit immune cell infiltration to reinforce inflammation specifically at this key pathogenic site.

Thus it becomes apparent how localized changes in the tissue occurring in RA direct site-specific aspects of pathology, and might explain the fact that targeting cytokines in RA is not enough to cure this disease. However, a systematic cellular atlas that describes the spatio-temporal organization of synovial cells is missing; little is known

about how many different cell subsets make up this tissue, nor their organization into functional networks.

Single cell resolution of the RA synovium

A step change in our ability to perform a cellular census of the cell types present in synovial joints has occurred because of advances in minimally invasive ultrasound-guided biopsy techniques, coupled with tissue digestion and single cell (sc) RNA sequencing²⁷⁻²⁹. Using these precision molecular analytics, multiparameter imaging and state of the art bioinformatics, recent work from tissue in the inflamed joint has revealed further insight into the complexity of the synovium, showing the RA synovium to be comprised of at least 18 distinct types of types of T cells, B cells, macrophages and fibroblasts²⁹ and allowing us to compile for the first time a synovial map of the leucocyte and stromal cells in the synovium in diseases such as OA and RA^{29,30}(**Figure 2**).

These studies have revealed unprecedented insight into anatomical and functional specialization of synovial cells. It has long been known that not only T cell number, but also the balance amongst T cell polarization, is a key determinant of immune status, for example lower ratios of Tregs compared to Th17 subsets contribute to impaired immune restraint and chronicity of inflammation³¹. Now, in the human RA joint, the existence of a pathogenic T cell population (termed TPh) that express high levels of PD1 but not CXCR5, has been identified to be highly expanded in seropositive RA patients and not seronegative³². These data indicate complexity in the rheumatoid T cell compartment that have not been previously appreciated.

It is also now clear that synovial fibroblasts exhibit striking **positional** and phenotypic segregation, with inflammatory Thy1 positive populations predominating in the sublining layer and destructive populations in the intima or lining layer, together with a further, distinct, subpopulation populating the perivascular space.

Moreover, inflammatory populations of synovial fibroblasts have been shown to expand in the synovial sublining layer in RA compared to OA, contributing to immune dysregulation, whilst destructive populations in the lining layer are responsible for cartilage and bone destruction during disease³⁰ (**Table 1, top panel**). This degree of cellular resolution and functional delegation starts to unravel disease progression at a new level.

New details are also emerging around macrophage populations in the RA joint. Evidence suggests that tissue resident macrophages in the intima serve a barrier function that maintains immune privilege in the joint. This becomes compromised in RA, allowing unrestricted infiltration of monocyte-derived cells, whilst preventing inflammation in OA. In contrast, subintimal macrophages comprise heterogeneous monocyte- and tissue-derived populations, amongst which pro-inflammatory phenotypes dominate in RA³³ (**Table 1, bottom panel**). **An independent study also highlighted RA synovial macrophage heterogeneity, in this instance with a focus on comparative analysis of disease remission and disease flare. Four distinct subpopulations were identified, comprising nine discrete phenotypic states, amongst which two subpopulations (MerTK+TREM2hi and MerTK+LYVE1+) were enriched in people whose RA was in remission compared to those with active disease, and**

whose contraction was associated with increased risk of disease flare. These subsets can induce synovial repair responses via production of inflammation-resolving lipid mediators³⁴. Finally, the existence of HBEFG(+) macrophages and fibroblasts in the rheumatoid synovium that induce fibroblast invasiveness has provided insight into functional, pathogenic cellular interaction networks across subpopulations from different lineages³⁵.

Together these studies demonstrate how our understanding of the architecture of the joint has progressed from gross anatomy, through subsynovial structures, including pannus tissue and tertiary lymphoid structures, to the single cell level, and how this has enabled the emergence of a more complete cell atlas of the joint. These data have also shown how changes in the balance of synovial cellular ecosystems underpin chronic inflammation during the onset and progression of RA compared to OA. Some of the underlying drives of these changes are beginning to emerge, for example, the expansion of Thy1 positive fibroblasts in the RA sublining is NOTCH3 dependent³⁶, compared to the lining layer, where Thy1 negative fibroblasts, along with lining layer MerTK positive macrophages, contract in active disease. Moreover, the increases in the ratio of MerTK positive to negative macrophages in the RA synovium in patients in disease remission suggests that lining layer macrophages regulate remission in RA³⁴.

These data may aid in therapeutic strategies that target pathogenic cell populations in RA. For example, functional subclasses of fibroblasts have proven difficult to define, characterize and study in health and disease. Consequently, there are no

approved drugs that specifically target fibroblasts in human diseases. The recent identification of “pathogenic” fibroblast subpopulations³⁰ offers an attractive new, non-immunosuppressive therapeutic target. However, fibroblasts are a functionally heterogeneous group of cells that support discrete biological functions within the joint tissue. This has led to a therapeutic dilemma: which fibroblast subsets should be targeted and suppressed and which should be retained and augmented? A clear understanding of the biology and clinical significance of fibroblast heterogeneity is therefore essential to provide a coherent rationale for their therapeutic targeting in treatment of diseases such as RA. The selective targeting of pathogenic fibroblast subsets using anti-fibroblast monoclonal antibodies, analogous to B cell depletion using CD20 (rituximab), would complement other targeted therapies commonly used against leucocytes and their cell products^{37,38}. Improved resolution of RA synovial macrophage subsets also now offers the potential for additional arsenal in modulating pathogenic myeloid cell behaviour, with MerTK+ subsets, or anti-inflammatory mediators released by these cells during disease remission, offering tractable targets for boosting synovial repair processes³⁴.

However, despite a clearer picture of the cellular networks inhabiting the RA synovium, it still remains uncertain what initiates and maintains pathogenic behaviour in different cell subsets in RA.

Immunological geography

It is now clear that synovial cell networks compartmentalize in distinct microdomains within the healthy joint, and that distinct, sub-synovial, niches arise in the RA

synovium compared to OA during disease progression. It is also clear that synovial cells do not exist in a vacuum, and an understanding the microenvironmental cues that shape their phenotype will provide key insight into joint tissue homeostasis and disease. The extracellular matrix can impact cell behavior via a diverse range of mechanisms³⁹, all of which contribute to defining synovial tissue biology, discussed below and summarized in **Table 2 and Figure 3**.

Physical properties and mechanical cues

The extracellular matrix defines the physical properties of tissues. For example, synovial fluid is the richest source of hyaluronic acid (HA), a glycosaminoglycan (GAG) comprising polymeric disaccharide repeats, which protects cartilage from frictional damage⁴⁰. Coating of articular surfaces with lubricin, or proteoglycan 4, a mucinous glycoprotein also found in synovial fluid, is the major means of effective joint lubrication⁴¹. Matrix molecules also bind to other matrix molecules to form complex, multicomponent structural networks. For example the thin membrane of the synovial lining layer comprises types III, IV, V and VI collagen and laminin, which supports intimal cells and acts as a molecular sieve, controlling bidirectional solute transfer between the synovium and synovial fluid^{4,42}. This specific architecture is key to allowing controlled, bidirectional flow of cells and molecules between the synovium and the joint cavity, maintaining tissue structure and integrity, controlling synovial fluid content and volume, clearing up debris and maintaining immunological homeostasis⁴³.

In addition to structural functionalization, the mechanical properties of the matrix also provide key environmental cues to tissue resident cells. In this way, not only the molecular content of the matrix dictates cell behaviour, but also the physical structure of the matrix itself defines the mechanical cues derived from the tissue⁴⁴. For example, interstitial cell migration within the fibrous synovial microenvironment is regulated both by tissue microstructure, such as matrix alignment and porosity, and tissue micromechanics, such as tensile, compressive and shear moduli, which cells use directly to sense biophysical cues via integrin receptors⁴⁵. Emerging data also shows how changes in tissue mechanics controls immune cell plasticity and polarization. For example, spatial confinement restricts late events in the activation of pro-inflammatory macrophages⁴⁶, which may have implications in how immune responses are modulated as tissue stiffness changes with synovial hyperplasia and fibrosis. In a manner analogous to matrix stiffness within the tumor microenvironment emerging as a key determinant of cancer progression and treatment response^{47,48}, so too the influence of the mechanical properties of the synovium, derived from the matrix content and higher order organization, on disease progression in RA should be considered.

Tissue architecture and spatial positioning

The extracellular matrix controls the spatial positioning of cells within tissues. For example, both lubricin and HA exert anti-adhesive properties which prevents cell adhesion at smooth articulated surfaces within joints that would be impeded by cell occupancy⁴. Conversely, deposition of the pro-adhesive matrix molecule fibronectin within the synovial lining layer membrane helps to maintain cellular interaction

networks by anchoring synovial fibroblasts to their surrounding matrix⁴⁹. Ectopic expression of fibronectin in the RA joint enables aberrant cell adhesion, for example, high levels of fibronectin in the pannus enhance synovial fibroblast adhesion to cartilage, stabilizing invadopodia, actin-rich protrusions of the plasma membrane that are associated with tissue degradation, by promoting coherent points of anchorage that facilitate cartilage invasion⁵⁰. Expression of fibronectin at the basal lamina and at the endothelial surface in inflamed synovium has also been proposed to serve as a permissive migration track for infiltrating lymphocytes, enabling T cells to cross the endothelial basement membrane in RA^{51,52}. The matrix also plays a key role in restricting cell migration, with the synovial membrane serving a barrier function to maintain immune privilege in the synovium, which is disrupted in RA³³.

Patterning of soluble factors

Soluble factors such as cytokines, chemokines and growth factors, by virtue of their being secreted by cells, are part of the matrisome (**Box 1**). The role of several of these inflammatory mediators in RA is well documented, and forms the basis for a number of key current biological therapies used to treat people with RA⁵³. However, within tissues these molecules often require interaction with other matrisomal components to signal, and their presentation, concentration and bio-availability throughout the synovium provides key context for their function. Indeed, core matrisomal molecules have been shown to control the localization of soluble factors in tissues, and are key determinants of their activity. Chemokine immobilization by GAGs, in particular heparan sulfate proteoglycans (HSPGs), at the luminal endothelial surface of blood vessels establishes chemokine gradients for migrating leukocytes⁵⁴,

as well as protecting these soluble factors from degradation⁵⁵, and facilitating oligomerization required for optimal activity⁵⁶. For example, in the RA synovium elevated expression of the HSPG syndecan-3 tethers CXCL8 in the endothelial lumen, and this interaction has been shown to promote leukocyte trafficking into the inflamed tissue in vivo during antigen-induced arthritis^{57,58}. The matrix is an essential reservoir for other soluble factors including cytokines, bone morphogenetic proteins (BMPs), Wnts and growth factors, where binding is often promiscuous, but is specific. For example, fibronectin, vitronectin, tenascin-C, osteopontin, type I collagen and fibrinogen each bind to several soluble factors from amongst the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor (TGF), insulin-like growth factor (IGF) and BMP families. However, each matrix molecule has a distinct set of soluble binding partners. Moreover, these molecules bind with different affinities across each family of growth factors; e.g. tenascin-C binds to VEGF-B but not VEGF-A, vitronectin binds to FGF-18, whilst tenascin-C does not, and neither bind to FGF-1 or -6⁵⁹. These interactions not only control tissue levels and locations of soluble factors, but are also essential for their function by serving as co-receptors. Proteoglycans in particular are well documented accessory molecules⁶⁰, with syndecans playing key roles in cartilage breakdown and synovial inflammation⁶¹. For example, optimal activity of FGF2, a growth factor up-regulated in RA, where it contributes to driving fibroblast activation during disease progression⁶², requires the formation of a ternary complex between the HS chains of syndecan-4 and the FGF receptor, as well as signaling via cytoplasmic domain of syndecan-4 to strengthen the duration and intensity of downstream signaling upon ligand binding⁶³. As such,

the role of many soluble factors may not be fully understood without examining how they interact with other extracellular tissue components. Moreover, simply targeting the activity of individual soluble factors in RA may not represent the most effective, or tissue-specific means of modulating their activity.

Direct signalling to cells

Matrix molecules provide key biochemical signals directly to cells. By virtue of their ability to interact with a large repertoire of cell surface receptors, including integrins, they can influence cellular behaviour ranging from proliferation to survival to cell death, and differentiation. Small, soluble effector molecules tend to evoke relatively simple signaling pathways, for example TNF at 17kDa activates just two receptors, TNFR1 and TNFR2⁶⁴. In contrast, matrix molecules are much larger, multimodular molecules, with far more complex interaction partners. For example thrombospondin-1 is a 450kDa secreted glycoprotein with seven modular domains, that is elevated in RA serum and synovium^{65,66}, and which has at least 83 different ligands, including other matrix molecules and soluble factors, as well as a plethora of cell surface receptors⁶⁷. Direct cues from the tissue microenvironment play a key in maintaining tissue homeostasis. Endogenous danger signals are immunologically silent in healthy tissues, but which trigger inflammatory responses upon cellular stress or tissue damage. These can include alarmins, intracellular molecules that are released to the extracellular milieu during cell activation or death⁶⁸, as well as extracellular matrix molecules whose expression is upregulated or modulated upon tissue injury, or which undergo post-translation modification⁶⁹. These damage associated molecular patterns (DAMPs) are sensed by pattern receptors such as TLRs

and integrins, triggering innate immunity and shaping adaptive responses designed to restore homeostasis and activate tissue repair. In the joints of people who do not have RA, these signals are essential in order for cells to detect and respond to injury and insult. However, dysregulation of these pathways is emerging as a major cause of chronic inflammation and tissue destruction in RA. For example, tenascin-C is an extracellular matrix molecule that is not expressed in most healthy tissues including the joint, but is transiently upregulated following tissue injury where it activates TLR4-mediated inflammation. Typically downregulated and cleared from tissues following repair, tenascin-C accumulates at high levels in the synovium of people with RA. Expression of this pro-inflammatory matrix molecule is required for the persistence of joint inflammation and tissue destruction in several different models of arthritis⁷⁰⁻⁷².

These studies collectively exemplify how the extracellular matrix surrounding and supporting synovial cells plays a key role in dictating site-specific behavior within the synovium. Emerging data also indicate dysregulated signals from the matrix drive chronic inflammation in the joint during the pathogenesis of RA, and that targeting these signals may provide an effective means of restoring immune control.

The extracellular matrix in the pathogenesis of RA

Whole exome sequencing has identified new genetic variants associated with RA susceptibility, amongst which genes in extracellular matrix-receptor pathways were most highly enriched (COL4A4, COL6A5, COL11A1, COL11A2, HSPG2, ITGB5, LAMC1, THBS1, RASGRF1, FLNB, MYL5)⁷³. Microarray analysis comparing healthy and RA

synovium also revealed differentially expressed genes involved in cell adhesion and organization of the extracellular matrix (PTPRC, SDC1, CD8A, CD2, HLA-DPA1, ITGA4, HLA-DMB, CD6, HLA-DOB, PDCD1LG2, COL3A1, SDC1, COL1A2, INTGB2)⁷⁴. Whilst the impact of sequence variation, or up-regulation, of these genes in people with RA is not known, these data implicate changes in the matrix and microenvironment in disease pathogenesis.

Altered tissue turnover has long been a pathological hallmark of RA^{5,6,75,76}, and serum levels of matrix metabolites are commonly used biomarkers for joint remodeling and bone degradation^{77,78}. For example, the C-telopeptide fragment of type I collagen (CTX-I) generated by osteoclast-derived cathepsin K reflects bone resorption⁷⁹, whilst osteocalcin produced by mature osteoblasts, and the N-terminal type I procollagen propeptide (PINP) released during collagen fibril synthesis, reflect bone formation⁸⁰. Cartilage degradation is assayed by examining serum levels of cartilage oligomeric matrix protein (COMP)⁸¹, the C-terminal telopeptide of type II collagen (CTX-II)⁸², and C2M, a fragment of type II collagen⁸³. Synovial remodelling is reflected by high circulating C1M, C3M and C4M, fragments of type I, type III and type IV collagen generated by MMP cleavage⁸⁴⁻⁸⁷, or proteases implicated in tissue destruction, such as total MMP-3 or the activated form of MMP-3^{88,89}. A reduction in serum matrix metabolites accompanies positive response to therapies including tocilizumab, etanercept, methotrexate, adalimumab, and tofacitinib (for example; ^{86,90-93}). Analysis of these biomarkers at baseline can also predict people who will respond well to tocilizumab⁹⁰, as well as predicting lack of efficacy of Syk inhibition via fostamatinib on structural end points⁹⁴. These serological markers therefore

serve as reliable surrogates of tissue destruction in RA, and may prove useful in stratifying patient treatment response. Emerging data also show that matrix metabolites are not simply inert collateral damage released from joint tissue as disease progresses, but active players in RA pathogenesis.

Expression of the tissue-degrading enzyme MT1-MMP is elevated in the RA joint, at sites of pannus invasion into cartilage¹⁵. Collagen-induced upregulation of MT1-MMP via DDR2 activation on synovial fibroblasts is more pronounced in variants missing non-helical telopeptides compared with intact collagen fibrils, and is enhanced in response to damaged cartilage⁹⁵, suggesting a positive feedback loop in which collagen degradation reinforces further tissue destruction. Fragments of hyaluronic acid (HA) are also detected in RA synovial fluid⁹⁶. The size of HA fragments dictates the function of this glycan, for example low molecular weight (MW), but not high MW, fragments activate TLR2-mediated inflammation in macrophages⁹⁷. Fragments of osteopontin are also elevated in synovial fluid from people with RA⁹⁸. Thrombin cleavage of this matrix molecule creates a C-terminal fragment that induces CD44-dependent macrophage chemotaxis, and an N-terminal fragment that promotes β 3 integrin-mediated macrophage spreading and activation^{99,100}. These data suggest that elevated levels of matrix metabolites contribute to both tissue remodeling and inflammation in RA.

The pro-inflammatory activity of osteopontin fragments is further regulated by phosphorylation; whilst the chemotactic activity of the C-terminal fragment is independent of modification, macrophage activation leading to cytokine and MMP

release by the N-terminal fragment requires phosphorylation^{99,100}. Higher levels of phosphorylated osteopontin, and phosphorylated osteopontin fragments, were observed in synovial fluid from people with RA compared to OA patients, whilst total osteopontin levels did not discriminate RA from OA¹⁰¹, suggesting that both proteolytic processing and post-translational modification of the matrix contributes to disease activity. Indeed, autoantibodies recognizing citrullinated proteins (ACPA), the post-translational conversion of arginine to citrulline catalyzed by peptidyl arginine deiminases, are gold-standard diagnostic markers for RA¹⁰². ACPA recognize a number of modified matrix molecules (reviewed in ^{103,104}), including citrullinated epitopes in type II collagen¹⁰⁵, well-established pathogenic drivers of joint disease *in vivo*^{106,107}; citrullinated fibrinogen¹⁰⁸, levels of which predict higher DAS 28 scores¹⁰⁹; citrullinated tenascin-C¹¹⁰, which may delineate different disease aetiologies¹¹¹; citrullinated aggrecan, which correlate with higher frequencies of cit-aggrecan-specific T cells in people with RA¹¹², and citrullinated fibronectin¹¹³. Intra-articular injection of citrullinated collagen and fibrinogen enhances their arthritogenic potential compared to unmodified protein¹¹⁴⁻¹¹⁶. Moreover, citrullination of fibrin(ogen) and fibronectin *in vitro* enhances their pro-inflammatory capabilities¹¹⁷⁻¹¹⁹, whilst citrullination of collagen and fibronectin alters their integrin binding repertoire and capacity to support synovial cell adhesion^{113,118,120}. Citrullinated fibronectin also effectively promotes cell survival, in contrast to induction of apoptosis by the native molecule^{49,117}, whilst the modified form exhibits increased affinity for VEGF but is less effective at binding to, and inhibiting, the aggrecanase ADAMTS4^{121,122}. As such matrix modification can not only break tolerance, *i.e.* create novel antigen epitopes that lead to the generation of T and B cell responses

against endogenous molecules, it can also generate pathological protein variants that may exacerbate inflammation in the RA joint.

RA diagnosis: the truth is in the tissue

One question arising from the study of circulating matrix metabolites, or antibodies recognizing modified matrix, is how well these markers reflect tissue pathology in the joint. Examining collagen, fibrinogen and fibronectin ex vivo in synovial biopsies by immunohistochemistry has been used to assess the degree of fibrosis in the RA synovium¹²³. This approach, whilst more invasive than serological analysis, takes into account that synovial pathology is compartmentalized, allowing examination of disease pathogenesis in the context of synovial anatomy. These details are likely to be important. For example, microfibrillar-associated protein 4 (MFAP4), a matrix molecule that associates with elastin and collagen, is implicated in stromal hyperplasia and fibrosis in liver and lung disease¹²⁴. MFAP4 is found at similarly high levels in the serum and synovial fluid from people with RA and OA, compared to low levels in healthy controls. In the tissue, it is detected in synovial sub-lining arteriole vessel walls and in adventitial tissue at sites of immune cell infiltration. However, it is absent from the internal elastic membrane of vessels in RA synovia, whilst present at high levels at this site in OA synovia¹²⁵. The consequences of differential distribution of MFAP4 in OA and RA synovia are not yet clear, but these data highlight that alterations in local tissue architecture are not always reflected in 'bulk' serum or tissue analysis.

Whilst circulating biomarkers therefore can be correlative with tissue pathology, they are not always causal, and it is clear that changes in the serum do not mirror the totality of changes in the synovium. Work examining the distribution of tenascin-C exemplifies how important mechanistic detail can be lost without the context of tissue anatomy. Levels of this pro-inflammatory matrix molecule are elevated in RA serum and synovial fluid^{126,127}, correlating with bone erosion during disease, and predicting poor improvement in pain in response to anti-TNF treatment¹²⁷. In the RA synovium, tenascin-C is found predominantly in the sublining layer, where it is restricted to two specific niches; a dense matrix surrounding CD34 negative fibroblast populations, and close to CD34+ perivascular fibroblasts located underneath blood vessels at sites of lymphocyte infiltration¹²⁸. This highlights specific cellular targets for tenascin-C in the RA joint, which may have remained obscured without anatomical analysis, and directs further mechanistic investigation, for example what role tenascin-C might play in promoting prolonged activation of inflammatory signaling in fibroblasts^{71,129} or in modulating pericyte adhesion, migration¹³⁰ or differentiation¹³¹ during RA.

Considering the advances in our knowledge of the cellular and molecular basis of synovial inflammation, it is clear that analysis of cell subset interaction networks in the tissue (for example inflammatory versus destructive fibroblasts, TPh cell or HBEFG(+) macrophage burden), together with the microenvironmental cues that instruct their behavior, is likely the most accurate way to assess the underlying events driving RA, enabling more precise disease classification, leading to process driven patient stratification and better targeted therapeutic intervention. However,

whilst advances in synovial biopsy methodology have enabled safer and more practicable tissue acquisition, sometimes involving two or more repeat samples¹³², by design interrogation of tissue micro-niches may be subject to sampling heterogeneity, and approaches designed to image the synovium *in vivo* may provide a useful complement to tissue harvest. Positron emission tomography (PET) using targeted radiotracers to visualize specific matrix components including collagen¹³³ or fibronectin¹³⁴ is developing as a viable method to image tissue fibrosis *in vivo* (reviewed in ^{135,136}). PET imaging of GPVI-Fc, a fusion protein comprising the soluble human IgG1 Fc domain and the extracellular domain of platelet glycoprotein VI, a trans-membrane platelet glycoprotein that binds with high affinity to matrix molecules including collagen, fibronectin and fibrinogen is also emerging as a means to visualize changes in the synovium *in vivo*. This chimeric molecule has been used to image nascent exposure of extracellular matrix during tissue damage, and synthesis of new fibrous tissue in GPI-serum induced experimental arthritis¹³⁷. These approaches constitute the first steps towards detailed molecular analysis of the synovial matrix in real time *in vivo*.

Exploiting the tissue microenvironment for improved disease treatment

Understanding the cells and the synovial microenvironment at unparalleled resolution not only illuminates our understanding of the tissue biology of the joint, and provides insight into disease status and disease mechanisms, it is also paving the way for new therapeutic strategies. Targeting the extracellular matrix is being used to develop a wide variety of new treatments¹³⁸, and these have been applied to RA in a number of different ways (Table 3).

575

576 ***Advances in drug delivery.*** Exploiting the tissue specificity of matrix molecule
577 expression has led to new approaches in drug delivery. Linking established anti-
578 inflammatory agents to antibodies that recognize matrix molecules, which are not
579 found in healthy tissue but which are upregulated at disease sites, creates a new
580 class of immunomodulatory agent that can home to areas of disease, and deliver
581 localized, site-specific treatment. This approach has been comprehensively
582 reviewed in ¹³⁹, and is most recently exemplified by F8-IL10. F8-IL10, or DEKAVIL, is a
583 cytokine-antibody fusion protein, comprising a single-chain antibody variable
584 domain (Fv) fragment of antibody F8 and the anti-inflammatory cytokine IL10. F8
585 recognizes the extra domain A (EDA) of fibronectin, a foetally restricted splice
586 variant of this matrix molecule, which is re-expressed in adults at sites of
587 inflammation and in cancer. F8-IL10 exhibits targeted delivery of IL10 to the
588 inflamed synovium in murine models of arthritis, and to both clinically and sub-
589 clinically inflamed joints in people with RA¹⁴⁰. Whilst PET-CT imaging revealed
590 unexpected localization of F8-IL10 to the liver and spleen in people with RA, no
591 safety issues were reported in Phase 1b clinical trials¹⁴¹. This approach may
592 effectively overcome the lack of efficacy of systemically administered IL10. Indeed,
593 this immunocytokine inhibited the progression of established arthritis in the
594 collagen-induced mouse model when tested alone and in combination with
595 methotrexate¹⁴² and early signs of therapeutic benefit in over half of people treated
596 at Phase 1b¹⁴¹. F8-IL10, and other immunocytokines designed to deliver anti-
597 inflammatory agents directly to inflamed sites represent a novel class of therapeutic

agents that effectively target antigens at the site of inflammation, followed by local activity of the cytokine¹³⁹.

Engineered matrix binding. Engineering matrix-binding capabilities to anti-TNF antibodies also shows promise in improving the efficacy of targeting TNF following intra-articular injection. Whilst systemic TNF blockade can induce generalized immunosuppression, intra-articular administration of anti-TNF antibodies is limited by rapid drug clearance from inflamed joints. Chemical conjugation of the heparin binding domain of placenta-growth factor-1 (PIGF-2), which binds with high affinity to many different matrix molecules, to murine monoclonal anti-TNF antibodies increased antibody retention times in the joint and significantly improved clinical scores in collagen antibody induced arthritis (CAIA) compared to unconjugated antibody¹⁴³. Similarly, conjugating anti-TNF antibodies to the collagen binding domain of decorin improves antibody accumulation in inflamed paws during CAIA and suppressing disease progression more effectively than unmodified antibody¹⁴⁴. This approach might make feasible intra-articular drug administration for monoarthritis, and help limit off target effects of systemic immune suppression. TNF blockade has also been re-engineered using MMP-cleavable inhibitory peptides. Construction of a chimeric TNF receptor linking the trimerization domain of adiponectin (Acrp30) to the N-terminus of the extracellular domain of TNFR2 via an MMP2/9 substrate sequence creates a cap which blocks TNF access to TNFR, which is released by MMP cleavage. *In vitro* this successfully allows controlled binding of TNFR2 to TNF. If this can be recapitulated *in vivo*, allowing elevated MMP activation at sites of inflammation to enable TNF binding to soluble chimeric receptors,

precluding activation of cellular TNFR, this could provide a powerful means of conferring inflamed tissue selective TNF blockade¹⁴⁵.

Preventing matrix degradation. An altogether different strategy in treating RA has been to directly target the activity of matrix degradation in order to prevent excessive joint tissue destruction (reviewed in ^{146,147}). Whilst early approaches using broad-spectrum small molecule MMP inhibitors were fraught with unacceptable side effects, more recent attempts with specific protease inhibitors appear more promising. A recent phase 1b trial of MMP9 specific monoclonal antibodies showed this approach to be safe and well tolerated¹⁴⁸, and pre-clinical data show how combining TNF and MT1-MMP blockade confers long-term protection from inflammation and tissue damage in mice with collagen induced arthritis¹⁴⁹. These data highlight how inhibiting both inflammatory and tissue destructive processes can exert synergistic effects in established disease. However, targeting these mediators hits targets comparatively late events in RA pathogenesis, and new data have begun to reveal the possibility of intervening earlier in disease, before mis-regulated cytokine networks and tissue destruction are evident.

Manipulating soluble factor binding to the matrix. One elegant way to intervene at the point of leukocyte invasion into the inflamed synovium may be to use decoy chemokines. Engineered to have a higher affinity for GAG interaction sites, but to be incapable of competent signaling via chemokine receptors, these agents can effectively displace wild type chemokines from essential matrix binding sites, acting as powerful dominant negative chemokine inhibitors. For example, CXCL8 variants

with enhanced HSPG binding, and ablated CXCR1 or CXCR2 binding, reduced peri-articular neutrophil infiltration and inhibited leucocyte adhesion on the venule at the site of joint inflammation, resulting in inhibited leucocyte transmigration into the knee cavity during mBSA-induced experimental arthritis¹⁵⁰. Similarly, short-chain basic peptides representing the GAG-binding region of chemokines such as CXCL8 bind to HSPG with high affinity, reduced leukocyte migration through the endothelial cell layer in vitro, compete with intact CXCL8 for binding around the endothelium in human RA tissue, and reduce inflammation and neutrophil infiltration during antigen-induced arthritis *in vivo*¹⁵¹. Alternatively, administration of the soluble extracellular domain of syndecan-3 has been used to mop up unwanted chemokines in the joint. Soluble syndecan-3 inhibited CCL7-activated leukocyte migration in vitro, and ameliorated histological disease severity, concomitantly reducing the number of blood vessels staining positive for CCL7 in the inflamed synovium, during antigen- and collagen-induced models of RA¹⁵².

Targeting chronic pro-inflammatory signals from the matrix. Matrix molecules, however, are more than just postcode proteins with which to deliver existing drugs, placeholders for chemokines, or substrates for proteolytic degradation; they also play a key role in driving disease. By creating distinct niches within the RA joint they deliver aberrant pro-inflammatory signal to resident cell networks. Targeting these networks can be useful in early disease modulation. For example, thrombin-cleaved osteopontin binding to fibronectin at the cell surface of synovial fibroblasts aids B cell adhesion and stimulates the production of inflammatory cytokines¹⁵³. A scFV antibody recognizing osteopontin, which blocks its interaction with fibronectin,

effectively reduced synovial fibroblast migration and adhesion to B cells in vitro, and improved clinical score, synovial hyperplasia, cartilage damage, cytokine levels when given early during collagen-antibody induced arthritis¹⁵⁴. These data show how targeting key matrix interactions during disease onset can be useful in preventing the formation of immune permissive environments. Moreover, it is increasingly apparent that changes in the synovial microenvironment take place long before any overt clinical symptoms. For example, serum levels of both tenascin-C and ficolin-1, both secreted endogenous TLR4 agonists⁷², are elevated in people with early synovitis who go on to develop RA compared to people with synovitis that spontaneously resolves^{155,156}. Moreover, baseline levels of ficolin-1 predict disease remission¹⁵⁵. Furthermore, therapeutic monoclonal antibodies that inhibit TLR4 activation by the fibrinogen-like globe of tenascin-C prevent chronic inflammation and halt disease progression when given early during collagen-induced arthritis¹²⁸. These data suggest that identifying and targeting key events that precede disease development might pave the way for better outcomes by early intervention, and even raise the possibility of disease prevention in pre-symptomatic individuals. This new matrix modifying drug class acts by blocking signals from the inflamed synovium, therefore also offering the advantage of selective blockade of tissue and disease specific cues, rather than global immune suppression, suppressing the true drivers of disease, but leaving intact our ability to respond to infection.

Challenges and perspectives

Whilst these therapeutic approaches appear promising, with some already in early clinical trials¹⁴⁰, and others opening up potential windows for very early disease

intervention or even prevention¹⁵⁷, many questions remain. At the most fundamental level, we do not yet have a full picture of which combination of the >1000 strong matrisomal gene subset are expressed in the synovium, nor how the resultant proteins and proteoglycans are organized at the subsynovial level.

Advances in proteomic analysis of extracellular matrix (for example ^{158,159}) are providing much greater depth in interrogation of matrix constituents of tissues.

However, proteomic deconstruction is challenging for the synovium because large amounts of tissue are rarely available, particularly from healthy joints or early RA.

RNA sequencing of single cells from RA joints has provided striking resolution of gene expression at the subpopulation level. However, this approach alone does not capture the full complexity of the tissue microenvironment, which necessitates understanding not only gene expression, but also post-transcriptional processing, and protein post-translational modification, all key factors in dictating matrix assembly and function. Furthermore, high-resolution cellular analysis at a single snapshot in time makes it difficult to discern whether cell populations identified in this way represent distinct cell types (and lineages), or the same cell types at distinct points on a spectrum of phenotypic polarization.

Another challenge lies in understanding precisely how target cells respond to the integrated biochemical and mechanical signals provided by multicomponent, 3D tissue microenvironments. Many approaches to assessing cell phenotype require the isolation of cells from tissues, in order to assess, for example, their transcriptional status. However, the process of cell isolation has a profound effect

on cell phenotype itself, accounting for as much as 40% of the transcriptome^{160,161}. This makes it difficult to differentiate cell behaviour instructed in situ or that caused by the stress of cell purification. Technologies such as NICHE-seq¹⁶² or spatial transcriptomics¹⁶³ can now provide information about localized gene expression programs, whilst matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) can visualise the spatial distribution of molecules, such glycans, peptides or proteins, by their molecular masses¹⁶⁴. Used in parallel with multiplex imaging and improved capabilities in optical sectioning provided by light sheet microscopy, which enables good resolution imaging of intact tissues and organs¹⁶⁵, these methods can now be applied to better resolve the content of the matrix of the joint, and its organization at the single cell level in situ, and with this a potentially rich source of tractable new targets with which to diagnose and treat inflammatory joint disease.

When thinking about cellular response to the tissue microenvironment, it is worth considering how external cues contribute both to programming cell identity, as well as to orchestrating transient cellular activation states required to respond to dynamically fluctuating tissue conditions. It has been shown that in tissue-resident macrophages from different organs, the tissue environment is crucial in the creation and maintenance of organ-specific macrophage functions¹⁶⁶, although the full extent of how integrated external signals programme this positional memory remains to be completely unravelled. Most likely tissue-derived signals also shape fibroblasts from different organs and differences in the epigenetic landscape, gene expression and response to stimulus were found by comparing cultured synovial and dermal

fibroblasts, suggesting a stable imprinting of organ-specific gene expression even when dissociated from tissue architecture¹⁶⁷⁻¹⁶⁹. On the other hand, in synovial¹⁷⁰, dermal¹⁷¹ and intestinal fibroblasts¹⁷² expression of HOX genes, which govern positional cellular identities during embryonic development, differs between different anatomical regions, which shows that also the anatomical site shapes cellular gene expression illustrated by the various differences found between hip, knee and ankle joints^{170,173-177}. Mechanical stimulation of joint cells is a well-established driver of cell identity during embryonic development¹⁷⁸ as well as postnatally and also influences the composition of the extracellular matrix^{179,180}. Together these data implicate that at different anatomical sites, differences in embryonic development as well as environmental cues induce changes in the content and structure of the synovial microenvironment and define cell behaviour at a transcriptomic and epigenetic level, which could at least partly explain the specific pattern of joint involvement seen in many joint diseases (**Figure 4**).

Conclusions

Interrogation of synovial cell populations using single cell transcriptomics, and mapping the location of cell subsets identified by this approach within tissues, is revealing detailed anatomical complexity in the synovium. Our understanding of the cellular basis of synovial health and disease has been accelerated by examination of how specialized cell networks function within discrete synovial neighbourhoods. In parallel, analysis of the role of microenvironment in defining synovial tissue structure and function is starting to reveal how extracellular cues are essential in organizing cell networks, and directing niche-specific cell behavior. These data also

change our thinking about how inflammatory joint disease arises and progresses, supporting more holistic consideration of synovial cell ecosystems, wherein communication between multiple different cell types and their surrounding matrix within discreet but interconnected neighbourhoods in the synovium, is essential for tissue homeostasis. Perturbations in any aspect of these symbiotic ecosystems are deleterious to synovial homeostasis, and can be pathogenic. We are already starting to see how this new perspective has the potential to change clinical practice. This is evident both in terms of disease diagnosis and classification, for example in efforts to use local changes in synovial tissue to better assess patient disease status, as well as in offering new treatment options. These may either improve the efficacy or specificity of drugs currently used to treat people with RA, or offer completely novel approaches to ameliorating disease.

Total word count: 7733

References

- 1 Amit, I., Winter, D. R. & Jung, S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. *Nat Immunol* **17**, 18-25, doi:10.1038/ni.3325 (2016).
- 2 Chang, H. Y. *et al.* Diversity, topographic differentiation, and positional memory in human fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America* **99**, 12877-12882, doi:10.1073/pnas.162488599 (2002).
- 3 Naba, A. *et al.* The extracellular matrix: Tools and insights for the "omics" era. *Matrix Biol* **49**, 10-24, doi:10.1016/j.matbio.2015.06.003 (2016).
- 4 Smith, M. D. The normal synovium. *Open Rheumatol J* **5**, 100-106, doi:10.2174/1874312901105010100 (2011).
- 5 McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* **365**, 2205-2219, doi:10.1056/NEJMra1004965 (2011).
- 6 Firestein, G. S. Evolving concepts of rheumatoid arthritis. *Nature* **423**, 356-361, doi:10.1038/nature01661 (2003).
- 7 Pitzalis, C., Kelly, S. & Humby, F. New learnings on the pathophysiology of RA from synovial biopsies. *Current opinion in rheumatology* **25**, 334-344, doi:10.1097/BOR.0b013e32835fd8eb (2013).

- 8 Nerviani, A. & Pitzalis, C. Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. *J Leukoc Biol* **104**, 333-341, doi:10.1002/JLB.3MR0218-062R (2018).
- 9 Dennis, G., Jr. *et al.* Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. *Arthritis research & therapy* **16**, R90, doi:10.1186/ar4555 (2014).
- 10 O'Sullivan, F. X., Fassbender, H. G., Gay, S. & Koopman, W. J. Etiopathogenesis of the rheumatoid arthritis-like disease in MRL/l mice. I. The histomorphologic basis of joint destruction. *Arthritis Rheum* **28**, 529-536, doi:10.1002/art.1780280511 (1985).
- 11 Geiler, T., Kriegsmann, J., Keyszer, G. M., Gay, R. E. & Gay, S. A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice. *Arthritis Rheum* **37**, 1664-1671, doi:10.1002/art.1780371116 (1994).
- 12 Muller-Ladner, U. *et al.* Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. *Am J Pathol* **149**, 1607-1615 (1996).
- 13 Kurowska-Stolarska, M. *et al.* Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. *Arthritis Rheum* **60**, 3663-3675, doi:10.1002/art.25001 (2009).
- 14 Jungel, A. *et al.* Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. *Ann Rheum Dis* **69**, 898-902, doi:10.1136/ard.2008.106021 (2010).
- 15 Pap, T. *et al.* Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. *Arthritis Rheum* **43**, 1226-1232, doi:10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4 (2000).
- 16 Seibl, R. *et al.* Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. *Am J Pathol* **162**, 1221-1227, doi:10.1016/S0002-9440(10)63918-1 (2003).
- 17 Firestein, G. S. *et al.* Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. *Am J Pathol* **149**, 2143-2151 (1996).
- 18 Seemayer, C. A. *et al.* p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. *Ann Rheum Dis* **62**, 1139-1144, doi:10.1136/ard.2003.007401 (2003).
- 19 Franz, J. K. *et al.* Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. *Arthritis Rheum* **43**, 599-607 (2000).
- 20 Pap, T. *et al.* Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. *Arthritis Res* **2**, 59-64, doi:10.1186/ar69 (2000).
- 21 Neidhart, M. *et al.* Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. *Arthritis Rheum* **43**, 2634-2647, doi:10.1002/1529-0131(200012)43:12<2634::AID-ANR3>3.0.CO;2-1 (2000).
- 22 Karouzakis, E., Gay, R. E., Gay, S. & Neidhart, M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. *Nat Rev Rheumatol* **5**, 266-272, doi:10.1038/nrrheum.2009.55 (2009).
- 23 Mendez-Huergo, S. P. *et al.* Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity. *Front Immunol* **9**, 3057, doi:10.3389/fimmu.2018.03057 (2018).
- 24 Ohshima, S. *et al.* Galectin 3 and its binding protein in rheumatoid arthritis. *Arthritis and rheumatism* **48**, 2788-2795 (2003).
- 25 Filer, A. *et al.* Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. *Arthritis Rheum* **60**, 1604-1614, doi:10.1002/art.24574 (2009).
- 26 Arad, U. *et al.* Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts. *Cytokine* **73**, 30-35, doi:10.1016/j.cyto.2015.01.016 (2015).
- 27 Mizoguchi, F. *et al.* Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. *Nat Commun* **9**, 789, doi:10.1038/s41467-018-02892-y (2018).
- 28 Stephenson, W. *et al.* Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. *Nat Commun* **9**, 791, doi:10.1038/s41467-017-02659-x (2018).

854 29 Zhang, F. *et al.* Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues
855 by integrating single-cell transcriptomics and mass cytometry. *Nature immunology* **20**, 928-
856 942, doi:10.1038/s41590-019-0378-1 (2019).

857 30 Croft, A. P. *et al.* Distinct fibroblast subsets drive inflammation and damage in arthritis.
858 *Nature* **570**, 246-251, doi:10.1038/s41586-019-1263-7 (2019).

859 31 Littman, D. R. & Rudensky, A. Y. Th17 and regulatory T cells in mediating and restraining
860 inflammation. *Cell* **140**, 845-858, doi:10.1016/j.cell.2010.02.021 (2010).

861 32 Rao, D. A. *et al.* Pathologically expanded peripheral T helper cell subset drives B cells in
862 rheumatoid arthritis. *Nature* **542**, 110-114, doi:10.1038/nature20810 (2017).

863 33 Culemann, S. *et al.* Locally renewing resident synovial macrophages provide a protective
864 barrier for the joint. *Nature*, doi:10.1038/s41586-019-1471-1 (2019).

865 34 Alivernini, S. *et al.* Distinct synovial tissue macrophage subsets regulate inflammation and
866 remission in rheumatoid arthritis. *Nat Med*, doi:10.1038/s41591-020-0939-8 (2020).

867 35 Kuo, D. *et al.* HBEGF(+) macrophages in rheumatoid arthritis induce fibroblast invasiveness.
868 *Sci Transl Med* **11**, doi:10.1126/scitranslmed.aau8587 (2019).

869 36 Wei, K. *et al.* Notch signalling drives synovial fibroblast identity and arthritis pathology.
870 *Nature* **582**, 259-264, doi:10.1038/s41586-020-2222-z (2020).

871 37 Filer, A. The fibroblast as a therapeutic target in rheumatoid arthritis. *Curr Opin Pharmacol*
872 **13**, 413-419, doi:10.1016/j.coph.2013.02.006 (2013).

873 38 Sherlock, J. P., Filer, A. D., Isaacs, J. D. & Buckley, C. D. What can rheumatologists learn from
874 translational cancer therapy? *Arthritis Res Ther* **15**, 114, doi:10.1186/ar4203 (2013).

875 39 Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer
876 progression. *J Cell Biol* **196**, 395-406, doi:10.1083/jcb.201102147 (2012).

877 40 Tamer, T. M. Hyaluronan and synovial joint: function, distribution and healing. *Interdiscip*
878 *Toxicol* **6**, 111-125, doi:10.2478/intox-2013-0019 (2013).

879 41 Jay, G. D. & Waller, K. A. The biology of lubricin: near frictionless joint motion. *Matrix Biol* **39**,
880 17-24, doi:10.1016/j.matbio.2014.08.008 (2014).

881 42 Gay, S., Gay, R. E. & Miller, E. F. The collagens of the joint. *Arthritis Rheum* **23**, 937-941,
882 doi:10.1002/art.1780230810 (1980).

883 43 Ouboussad, L., Burska, A. N., Melville, A. & Buch, M. H. Synovial Tissue Heterogeneity in
884 Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform
885 Stratified Therapy. *Front Med (Lausanne)* **6**, 45, doi:10.3389/fmed.2019.00045 (2019).

886 44 Miller, A. E., Hu, P. & Barker, T. H. Feeling Things Out: Bidirectional Signaling of the Cell-ECM
887 Interface, Implications in the Mechanobiology of Cell Spreading, Migration, Proliferation, and
888 Differentiation. *Adv Healthc Mater* **9**, e1901445, doi:10.1002/adhm.201901445 (2020).

889 45 Qu, F., Guilak, F. & Mauck, R. L. Cell migration: implications for repair and regeneration in
890 joint disease. *Nat Rev Rheumatol* **15**, 167-179, doi:10.1038/s41584-018-0151-0 (2019).

891 46 Jain, N., Moeller, J. & Vogel, V. Mechanobiology of Macrophages: How Physical Factors
892 Coregulate Macrophage Plasticity and Phagocytosis. *Annu Rev Biomed Eng* **21**, 267-297,
893 doi:10.1146/annurev-bioeng-062117-121224 (2019).

894 47 Piersma, B., Hayward, M. K. & Weaver, V. M. Fibrosis and cancer: A strained relationship.
895 *Biochim Biophys Acta Rev Cancer* **1873**, 188356, doi:10.1016/j.bbcan.2020.188356 (2020).

896 48 Northcott, J. M., Dean, I. S., Mouw, J. K. & Weaver, V. M. Feeling Stress: The Mechanics of
897 Cancer Progression and Aggression. *Front Cell Dev Biol* **6**, 17, doi:10.3389/fcell.2018.00017
898 (2018).

899 49 Shelef, M. A., Bennin, D. A., Mosher, D. F. & Huttenlocher, A. Citrullination of fibronectin
900 modulates synovial fibroblast behavior. *Arthritis research & therapy* **14**, R240,
901 doi:10.1186/ar4083 (2012).

902 50 Mueller, S. C. & Chen, W. T. Cellular invasion into matrix beads: localization of beta 1
903 integrins and fibronectin to the invadopodia. *J Cell Sci* **99 (Pt 2)**, 213-225 (1991).

904 51 van Dinther-Janssen, A. C., Pals, S. T., Scheper, R. J. & Meijer, C. J. Role of the CS1 adhesion
905 motif of fibronectin in T cell adhesion to synovial membrane and peripheral lymph node
906 endothelium. *Ann Rheum Dis* **52**, 672-676, doi:10.1136/ard.52.9.672 (1993).

907 52 Simon, M. M., Kramer, M. D., Prester, M. & Gay, S. Mouse T-cell associated serine proteinase
908 1 degrades collagen type IV: a structural basis for the migration of lymphocytes through
909 vascular basement membranes. *Immunology* **73**, 117-119 (1991).

53 Lubberts, E. & van den Berg, W. B. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. *Adv Exp Med Biol* **520**, 194-202, doi:10.1007/978-1-4615-0171-8_11 (2003).

54 Middleton, J., Patterson, A. M., Gardner, L., Schmutz, C. & Ashton, B. A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. *Blood* **100**, 3853-3860, doi:10.1182/blood.V100.12.3853 (2002).

55 Sadir, R., Imberty, A., Baleux, F. & Lortat-Jacob, H. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. *J Biol Chem* **279**, 43854-43860, doi:10.1074/jbc.M405392200 (2004).

56 Johnson, Z. *et al.* Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. *J Immunol* **173**, 5776-5785, doi:10.4049/jimmunol.173.9.5776 (2004).

57 Kehoe, O. *et al.* Syndecan-3 is selectively pro-inflammatory in the joint and contributes to antigen-induced arthritis in mice. *Arthritis Res Ther* **16**, R148, doi:10.1186/ar4610 (2014).

58 Patterson, A. M. *et al.* Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. *Arthritis Rheum* **52**, 2331-2342, doi:10.1002/art.21222 (2005).

59 Martino, M. M. *et al.* Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. *Science* **343**, 885-888, doi:10.1126/science.1247663 (2014).

60 Mythreye, K. & Blobel, G. C. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. *Cell Signal* **21**, 1548-1558, doi:10.1016/j.cellsig.2009.05.001 (2009).

61 Pap, T. & Bertrand, J. Syndecans in cartilage breakdown and synovial inflammation. *Nat Rev Rheumatol* **9**, 43-55, doi:10.1038/nrrheum.2012.178 (2013).

62 Shao, X. *et al.* FGF2 cooperates with IL-17 to promote autoimmune inflammation. *Sci Rep* **7**, 7024, doi:10.1038/s41598-017-07597-8 (2017).

63 Elfenbein, A. & Simons, M. Syndecan-4 signaling at a glance. *J Cell Sci* **126**, 3799-3804, doi:10.1242/jcs.124636 (2013).

64 Bazzoni, F. & Beutler, B. The tumor necrosis factor ligand and receptor families. *N Engl J Med* **334**, 1717-1725, doi:10.1056/NEJM199606273342607 (1996).

65 Rico, M. C. *et al.* Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis. *Transl Res* **152**, 95-98, doi:10.1016/j.trsl.2008.06.002 (2008).

66 Suzuki, T. *et al.* Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of Rheumatoid Arthritis: Role of Transforming Growth Factor-beta1 toward Fibroblast-like Synovial Cells. *J Rheumatol* **42**, 943-947, doi:10.3899/jrheum.141292 (2015).

67 Resovi, A., Pinessi, D., Chiorino, G. & Tarabozetti, G. Current understanding of the thrombospondin-1 interactome. *Matrix Biol* **37**, 83-91, doi:10.1016/j.matbio.2014.01.012 (2014).

68 Nefla, M., Holzinger, D., Berenbaum, F. & Jacques, C. The danger from within: alarmins in arthritis. *Nat Rev Rheumatol* **12**, 669-683, doi:10.1038/nrrheum.2016.162 (2016).

69 Frevert, C. W., Felgenhauer, J., Wygrecka, M., Nastase, M. V. & Schaefer, L. Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity. *J Histochem Cytochem* **66**, 213-227, doi:10.1369/0022155417740880 (2018).

70 Marzeda, A. M. & Midwood, K. S. Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity. *J Histochem Cytochem* **66**, 289-304, doi:10.1369/0022155418757443 (2018).

71 Midwood, K. *et al.* Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. *Nat Med* **15**, 774-780, doi:10.1038/nm.1987 (2009).

72 Zuliani-Alvarez, L. *et al.* Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers. *Nat Commun* **8**, 1595, doi:10.1038/s41467-017-01718-7 (2017).

73 Li, Y. *et al.* Identification of potential genetic causal variants for rheumatoid arthritis by whole-exome sequencing. *Oncotarget* **8**, 11119-11129, doi:10.18632/oncotarget.22630 (2017).

966 74 Xiong, Y. *et al.* Bioinformatics Analysis and Identification of Genes and Molecular Pathways
967 Involved in Synovial Inflammation in Rheumatoid Arthritis. *Med Sci Monit* **25**, 2246-2256,
968 doi:10.12659/MSM.915451 (2019).

969 75 Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and
970 disease. *Nat Rev Mol Cell Biol* **15**, 786-801, doi:10.1038/nrm3904 (2014).

971 76 Karouzakis, E., Neidhart, M., Gay, R. E. & Gay, S. Molecular and cellular basis of rheumatoid
972 joint destruction. *Immunol Lett* **106**, 8-13, doi:10.1016/j.imlet.2006.04.011 (2006).

973 77 Garnero, P., Rousseau, J. C. & Delmas, P. D. Molecular basis and clinical use of biochemical
974 markers of bone, cartilage, and synovium in joint diseases. *Arthritis Rheum* **43**, 953-968,
975 doi:10.1002/1529-0131(200005)43:5<953::AID-ANR1>3.0.CO;2-Q (2000).

976 78 Karsdal, M. A. *et al.* Biochemical markers of ongoing joint damage in rheumatoid arthritis--
977 current and future applications, limitations and opportunities. *Arthritis Res Ther* **13**, 215,
978 doi:10.1186/ar3280 (2011).

979 79 Aschenberg, S. *et al.* Catabolic and anabolic periarticular bone changes in patients with
980 rheumatoid arthritis: a computed tomography study on the role of age, disease duration and
981 bone markers. *Arthritis Res Ther* **15**, R62, doi:10.1186/ar4235 (2013).

982 80 Chapurlat, R. D. & Confavreux, C. B. Novel biological markers of bone: from bone metabolism
983 to bone physiology. *Rheumatology (Oxford)* **55**, 1714-1725,
984 doi:10.1093/rheumatology/kev410 (2016).

985 81 Saxne, T. & Heinegard, D. Cartilage oligomeric matrix protein: a novel marker of cartilage
986 turnover detectable in synovial fluid and blood. *Br J Rheumatol* **31**, 583-591,
987 doi:10.1093/rheumatology/31.9.583 (1992).

988 82 Christensen, A. F. *et al.* Differential association of the N-propeptide of collagen IIA (PIIANP)
989 and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding
990 rheumatoid arthritis. *Clin Exp Rheumatol* **27**, 307-314 (2009).

991 83 Bay-Jensen, A. C. *et al.* Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase
992 derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe
993 radiographic osteoarthritis. *Clin Biochem* **44**, 423-429,
994 doi:10.1016/j.clinbiochem.2011.01.001 (2011).

995 84 Barascuk, N. *et al.* A novel assay for extracellular matrix remodeling associated with liver
996 fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically
997 revealed neo-epitope of type III collagen. *Clin Biochem* **43**, 899-904,
998 doi:10.1016/j.clinbiochem.2010.03.012 (2010).

999 85 Bay-Jensen, A. C. *et al.* Circulating protein fragments of cartilage and connective tissue
1000 degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing
1001 spondylitis. *PLoS One* **8**, e54504, doi:10.1371/journal.pone.0054504 (2013).

1002 86 Gudmann, N. S. *et al.* Increased remodelling of interstitial collagens and basement
1003 membrane is suppressed by treatment in patients with rheumatoid arthritis: serological
1004 evaluation of a one-year prospective study of 149 Japanese patients. *Clin Exp Rheumatol* **36**,
1005 462-470 (2018).

1006 87 Leeming, D. *et al.* A novel marker for assessment of liver matrix remodeling: an enzyme-
1007 linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope
1008 (C1M). *Biomarkers* **16**, 616-628, doi:10.3109/1354750X.2011.620628 (2011).

1009 88 Ma, J. D. *et al.* Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological
1010 synovitis for diagnosis of rheumatoid arthritis. *Mediators Inflamm* **2014**, 179284,
1011 doi:10.1155/2014/179284 (2014).

1012 89 Sun, S. *et al.* The active form of MMP-3 is a marker of synovial inflammation and cartilage
1013 turnover in inflammatory joint diseases. *BMC Musculoskelet Disord* **15**, 93,
1014 doi:10.1186/1471-2474-15-93 (2014).

1015 90 Bay-Jensen, A. C. *et al.* Serological biomarkers of joint tissue turnover predict tocilizumab
1016 response at baseline. *J Clin Rheumatol* **20**, 332-335, doi:10.1097/RHU.0000000000000150
1017 (2014).

1018 91 Bay-Jensen, A. C. *et al.* Effect of tocilizumab combined with methotrexate on circulating
1019 biomarkers of synovium, cartilage, and bone in the LITHE study. *Semin Arthritis Rheum* **43**,
1020 470-478, doi:10.1016/j.semarthrit.2013.07.008 (2014).

1021 92 Gudmann, N. S. *et al.* Type IV collagen metabolism is associated with disease activity,
1022 radiographic progression and response to tocilizumab in rheumatoid arthritis. *Clin Exp*
1023 *Rheumatol* **36**, 829-835 (2018).

1024 93 Juhl, P. *et al.* IL-6 receptor inhibition modulates type III collagen and C-reactive protein
1025 degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour
1026 necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE
1027 study. *Clin Exp Rheumatol* **36**, 568-574 (2018).

1028 94 Kjelgaard-Petersen, C. F. *et al.* Translational Biomarkers and Ex Vivo Models of Joint Tissues
1029 as a Tool for Drug Development in Rheumatoid Arthritis. *Arthritis Rheumatol* **70**, 1419-1428,
1030 doi:10.1002/art.40527 (2018).

1031 95 Majkowska, I., Shitomi, Y., Ito, N., Gray, N. S. & Itoh, Y. Discoidin domain receptor 2 mediates
1032 collagen-induced activation of membrane-type 1 matrix metalloproteinase in human
1033 fibroblasts. *J Biol Chem* **292**, 6633-6643, doi:10.1074/jbc.M116.770057 (2017).

1034 96 Nagy, N. *et al.* Hyaluronan in immune dysregulation and autoimmune diseases. *Matrix Biol*
1035 **78-79**, 292-313, doi:10.1016/j.matbio.2018.03.022 (2019).

1036 97 Scheibner, K. A. *et al.* Hyaluronan fragments act as an endogenous danger signal by engaging
1037 TLR2. *J Immunol* **177**, 1272-1281, doi:10.4049/jimmunol.177.2.1272 (2006).

1038 98 Hasegawa, M. *et al.* Thrombin-cleaved osteopontin in synovial fluid of subjects with
1039 rheumatoid arthritis. *J Rheumatol* **36**, 240-245, doi:10.3899/jrheum.080753 (2009).

1040 99 Kazanecki, C. C., Uzwiak, D. J. & Denhardt, D. T. Control of osteopontin signaling and function
1041 by post-translational phosphorylation and protein folding. *J Cell Biochem* **102**, 912-924,
1042 doi:10.1002/jcb.21558 (2007).

1043 100 Weber, G. F. *et al.* Phosphorylation-dependent interaction of osteopontin with its receptors
1044 regulates macrophage migration and activation. *J Leukoc Biol* **72**, 752-761 (2002).

1045 101 Luukkonen, J. *et al.* Increased amount of phosphorylated proinflammatory osteopontin in
1046 rheumatoid arthritis synovia is associated to decreased tartrate-resistant acid phosphatase
1047 5B/5A ratio. *PLoS One* **12**, e0182904, doi:10.1371/journal.pone.0182904 (2017).

1048 102 Wegner, N. *et al.* Autoimmunity to specific citrullinated proteins gives the first clues to the
1049 etiology of rheumatoid arthritis. *Immunological reviews* **233**, 34-54, doi:10.1111/j.0105-
1050 2896.2009.00850.x (2010).

1051 103 Foster, M. H. Basement membranes and autoimmune diseases. *Matrix Biol* **57-58**, 149-168,
1052 doi:10.1016/j.matbio.2016.07.008 (2017).

1053 104 Steen, J. *et al.* Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human
1054 Plasma Cell-Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in
1055 Rheumatoid Arthritis. *Arthritis Rheumatol* **71**, 196-209, doi:10.1002/art.40699 (2019).

1056 105 Haag, S. *et al.* Identification of new citrulline-specific autoantibodies, which bind to human
1057 arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. *Arthritis*
1058 *Rheumatol* **66**, 1440-1449, doi:10.1002/art.38383 (2014).

1059 106 Burkhardt, H. *et al.* Epitope-specific recognition of type II collagen by rheumatoid arthritis
1060 antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced
1061 arthritis in the mouse. *Arthritis Rheum* **46**, 2339-2348, doi:10.1002/art.10472 (2002).

1062 107 Holmdahl, R., Jansson, L., Larsson, A. & Jonsson, R. Arthritis in DBA/1 mice induced with
1063 passively transferred type II collagen immune serum. Immunohistopathology and serum
1064 levels of anti-type II collagen auto-antibodies. *Scand J Immunol* **31**, 147-157,
1065 doi:10.1111/j.1365-3083.1990.tb02754.x (1990).

1066 108 Raats, J. M., Wijnen, E. M., Pruijn, G. J., van den Hoogen, F. H. & van Venrooij, W. J.
1067 Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides
1068 from phage display libraries derived from patients with rheumatoid arthritis. *J Rheumatol* **30**,
1069 1696-1711 (2003).

1070 109 Boman, A. *et al.* Antibodies against citrullinated peptides are associated with clinical and
1071 radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal
1072 inception cohort study. *RMD Open* **5**, e000946, doi:10.1136/rmdopen-2019-000946 (2019).

1073 110 Schwenzer, A. *et al.* Identification of an immunodominant peptide from citrullinated
1074 tenascin-C as a major target for autoantibodies in rheumatoid arthritis. *Ann Rheum Dis* **75**,
1075 1876-1883, doi:10.1136/annrheumdis-2015-208495 (2016).

1076 111 Schwenzer, A. *et al.* Association of Distinct Fine Specificities of Anti-Citrullinated Peptide
1077 Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of

1078 Patients With Rheumatoid Arthritis and Periodontitis. *Arthritis Rheumatol* **69**, 2303-2313,
1079 doi:10.1002/art.40227 (2017).

1080 112 Rims, C. *et al.* Citrullinated Aggrecan Epitopes as Targets of Autoreactive CD4+ T Cells in
1081 Patients With Rheumatoid Arthritis. *Arthritis Rheumatol* **71**, 518-528, doi:10.1002/art.40768
1082 (2019).

1083 113 Stefanelli, V. L. *et al.* Citrullination of fibronectin alters integrin clustering and focal adhesion
1084 stability promoting stromal cell invasion. *Matrix Biol* **82**, 86-104,
1085 doi:10.1016/j.matbio.2019.04.002 (2019).

1086 114 Lundberg, K. *et al.* Citrullinated proteins have increased immunogenicity and arthritogenicity
1087 and their presence in arthritic joints correlates with disease severity. *Arthritis Res Ther* **7**,
1088 R458-467, doi:10.1186/ar1697 (2005).

1089 115 Vossenaar, E. R. *et al.* Citrullination of synovial proteins in murine models of rheumatoid
1090 arthritis. *Arthritis Rheum* **48**, 2489-2500, doi:10.1002/art.11229 (2003).

1091 116 Ho, P. P. *et al.* Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. *J*
1092 *Immunol* **184**, 379-390, doi:10.4049/jimmunol.0901639 (2010).

1093 117 Fan, L. *et al.* Citrullinated fibronectin inhibits apoptosis and promotes the secretion of pro-
1094 inflammatory cytokines in fibroblast-like synoviocytes in rheumatoid arthritis. *Arthritis*
1095 *research & therapy* **14**, R266, doi:10.1186/ar4112 (2012).

1096 118 Sanchez-Pernaute, O. *et al.* Citrullination enhances the pro-inflammatory response to fibrin
1097 in rheumatoid arthritis synovial fibroblasts. *Ann Rheum Dis* **72**, 1400-1406,
1098 doi:10.1136/annrheumdis-2012-201906 (2013).

1099 119 Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing
1100 citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor.
1101 *Arthritis and rheumatism* **63**, 53-62, doi:10.1002/art.30081 (2011).

1102 120 Sipila, K. *et al.* Citrullination of collagen II affects integrin-mediated cell adhesion in a
1103 receptor-specific manner. *FASEB J* **28**, 3758-3768, doi:10.1096/fj.13-247767 (2014).

1104 121 Chang, X. *et al.* Citrullination of fibronectin in rheumatoid arthritis synovial tissue.
1105 *Rheumatology (Oxford, England)* **44**, 1374-1382, doi:10.1093/rheumatology/kei023 (2005).

1106 122 Yan, X., Yin, L., Wang, Y., Zhao, Y. & Chang, X. The low binding affinity of ADAMTS4 for
1107 citrullinated fibronectin may contribute to the destruction of joint cartilage in rheumatoid
1108 arthritis. *Clin Exp Rheumatol* **31**, 201-206 (2013).

1109 123 Zoumi, A., Yeh, A. & Tromberg, B. J. Imaging cells and extracellular matrix in vivo by using
1110 second-harmonic generation and two-photon excited fluorescence. *Proc Natl Acad Sci U S A*
1111 **99**, 11014-11019, doi:10.1073/pnas.172368799 (2002).

1112 124 Molleken, C. *et al.* MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?
1113 *Sarcoidosis Vasc Diffuse Lung Dis* **33**, 41-50 (2016).

1114 125 Christensen, A. F. *et al.* Site-specific absence of microfibrillar-associated protein 4 (MFAP4)
1115 from the internal elastic membrane of arterioles in the rheumatoid arthritis synovial
1116 membrane: an immunohistochemical study in patients with advanced rheumatoid arthritis
1117 versus osteoarthritis. *APMIS* **127**, 588-593, doi:10.1111/apm.12974 (2019).

1118 126 Hasegawa, M. *et al.* Expression of large tenascin-C splice variants in synovial fluid of patients
1119 with rheumatoid arthritis. *J Orthop Res* **25**, 563-568, doi:10.1002/jor.20366 (2007).

1120 127 Page, T. H. *et al.* Raised circulating tenascin-C in rheumatoid arthritis. *Arthritis Res Ther* **14**,
1121 R260, doi:10.1186/ar4105 (2012).

1122 128 Aungier, S. R. *et al.* Targeting early changes in the synovial microenvironment: a new class of
1123 immunomodulatory therapy? *Ann Rheum Dis* **78**, 186-191, doi:10.1136/annrheumdis-2018-
1124 214294 (2019).

1125 129 Asano, T. *et al.* α9β1 integrin acts as a critical intrinsic regulator of human rheumatoid
1126 arthritis. *Rheumatology (Oxford)* **53**, 415-424, doi:10.1093/rheumatology/ket371 (2014).

1127 130 Rupp, T. *et al.* Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and
1128 Anti-angiogenic Signaling. *Cell Rep* **17**, 2607-2619, doi:10.1016/j.celrep.2016.11.012 (2016).

1129 131 Kumar, A. *et al.* Specification and Diversification of Pericytes and Smooth Muscle Cells from
1130 Mesenchymoangioblasts. *Cell Rep* **19**, 1902-1916, doi:10.1016/j.celrep.2017.05.019 (2017).

1131 132 Orr, C. *et al.* Synovial tissue research: a state-of-the-art review. *Nat Rev Rheumatol* **13**, 463-
1132 475, doi:10.1038/nrrheum.2017.115 (2017).

1133 133 Muzard, J. *et al.* Non-invasive molecular imaging of fibrosis using a collagen-targeted
1134 peptidomimetic of the platelet collagen receptor glycoprotein VI. *PLoS One* **4**, e5585,
1135 doi:10.1371/journal.pone.0005585 (2009).

1136 134 Han, Z. & Lu, Z. R. Targeting Fibronectin for Cancer Imaging and Therapy. *J Mater Chem B* **5**,
1137 639-654, doi:10.1039/C6TB02008A (2017).

1138 135 Baues, M. *et al.* Fibrosis imaging: Current concepts and future directions. *Adv Drug Deliv Rev*
1139 **121**, 9-26, doi:10.1016/j.addr.2017.10.013 (2017).

1140 136 Desogere, P., Montesi, S. B. & Caravan, P. Molecular Probes for Imaging Fibrosis and
1141 Fibrogenesis. *Chemistry* **25**, 1128-1141, doi:10.1002/chem.201801578 (2019).

1142 137 Beziere, N. *et al.* Imaging fibrosis in inflammatory diseases: targeting the exposed
1143 extracellular matrix. *Theranostics* **9**, 2868-2881, doi:10.7150/thno.28892 (2019).

1144 138 Schultz, C. Targeting the extracellular matrix for delivery of bioactive molecules to sites of
1145 arthritis. *Br J Pharmacol* **176**, 26-37, doi:10.1111/bph.14516 (2019).

1146 139 Schmid, A. S. & Neri, D. Advances in antibody engineering for rheumatic diseases. *Nat Rev*
1147 *Rheumatol* **15**, 197-207, doi:10.1038/s41584-019-0188-8 (2019).

1148 140 Bruijnen, S. T. G. *et al.* F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-
1149 Guided Translational Approach. *Mol Pharm* **16**, 273-281,
1150 doi:10.1021/acs.molpharmaceut.8b00982 (2019).

1151 141 Galeazzi, M. *et al.* A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory
1152 'armed antibody' for the treatment of rheumatoid arthritis, used in combination with
1153 methotrexate. *Isr Med Assoc J* **16**, 666 (2014).

1154 142 Schwager, K. *et al.* Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage
1155 immunocytokine which inhibits the progression of collagen-induced arthritis. *Arthritis Res*
1156 *Ther* **11**, R142, doi:10.1186/ar2814 (2009).

1157 143 Katsumata, K. *et al.* Conferring extracellular matrix affinity enhances local therapeutic
1158 efficacy of anti-TNF-alpha antibody in a murine model of rheumatoid arthritis. *Arthritis Res*
1159 *Ther* **21**, 298, doi:10.1186/s13075-019-2075-8 (2019).

1160 144 Katsumata, K. *et al.* Targeting inflammatory sites through collagen affinity enhances the
1161 therapeutic efficacy of anti-inflammatory antibodies. *Sci Adv* **5**, eaay1971,
1162 doi:10.1126/sciadv.aay1971 (2019).

1163 145 Lee, C. J. *et al.* Development of an inflammatory tissue-selective chimeric TNF receptor.
1164 *Cytokine* **113**, 340-346, doi:10.1016/j.cyto.2018.10.003 (2019).

1165 146 Itoh, Y. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to
1166 Improve Current Therapies. *Prog Mol Biol Transl Sci* **148**, 327-338,
1167 doi:10.1016/bs.pmbts.2017.03.002 (2017).

1168 147 Malemud, C. J. Matrix Metalloproteinases and Synovial Joint Pathology. *Prog Mol Biol Transl*
1169 *Sci* **148**, 305-325, doi:10.1016/bs.pmbts.2017.03.003 (2017).

1170 148 Gossage, D. L. *et al.* Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related
1171 Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With
1172 Rheumatoid Arthritis. *Clin Ther* **40**, 156-165 e155, doi:10.1016/j.clinthera.2017.11.011
1173 (2018).

1174 149 Kaneko, K. *et al.* Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase
1175 Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis
1176 Factor Blockade. *Arthritis Rheumatol* **68**, 521-531, doi:10.1002/art.39414 (2016).

1177 150 Falsone, A. *et al.* Designing CXCL8-based decoy proteins with strong anti-inflammatory
1178 activity in vivo. *Biosci Rep* **33**, doi:10.1042/BSR20130069 (2013).

1179 151 McNaughton, E. F. *et al.* Novel Anti-Inflammatory Peptides Based on Chemokine-
1180 Glycosaminoglycan Interactions Reduce Leukocyte Migration and Disease Severity in a Model
1181 of Rheumatoid Arthritis. *J Immunol* **200**, 3201-3217, doi:10.4049/jimmunol.1701187 (2018).

1182 152 Eustace, A. D. *et al.* Soluble syndecan-3 binds chemokines, reduces leukocyte migration in
1183 vitro and ameliorates disease severity in models of rheumatoid arthritis. *Arthritis Res Ther*
1184 **21**, 172, doi:10.1186/s13075-019-1939-2 (2019).

1185 153 Take, Y. *et al.* Specifically modified osteopontin in rheumatoid arthritis fibroblast-like
1186 synoviocytes supports interaction with B cells and enhances production of interleukin-6.
1187 *Arthritis Rheum* **60**, 3591-3601, doi:10.1002/art.25020 (2009).

1188 154 Mehta, B. B. *et al.* Blocking osteopontin-fibronectin interactions reduce extracellular
1189 fibronectin deployment and arthritic immunopathology. *Int Immunopharmacol* **55**, 297-305,
1190 doi:10.1016/j.intimp.2017.12.028 (2018).

1191 155 Ammitzboll, C. G. *et al.* M-ficolin levels reflect disease activity and predict remission in early
1192 rheumatoid arthritis. *Arthritis Rheum* **65**, 3045-3050, doi:10.1002/art.38179 (2013).

1193 156 Raza, K. *et al.* Detection of antibodies to citrullinated tenascin-C in patients with early
1194 synovitis is associated with the development of rheumatoid arthritis. *RMD Open* **2**, e000318,
1195 doi:10.1136/rmdopen-2016-000318 (2016).

1196 157 Cutolo, M., Soldano, S. & Paolino, S. Potential roles for tenascin in (very) early diagnosis and
1197 treatment of rheumatoid arthritis. *Ann Rheum Dis*, doi:10.1136/annrheumdis-2019-215063
1198 (2019).

1199 158 Filipe, E. C., Chitty, J. L. & Cox, T. R. Charting the unexplored extracellular matrix in cancer. *Int*
1200 *J Exp Pathol* **99**, 58-76, doi:10.1111/iep.12269 (2018).

1201 159 Taha, I. N. & Naba, A. Exploring the extracellular matrix in health and disease using
1202 proteomics. *Essays Biochem* **63**, 417-432, doi:10.1042/EBC20190001 (2019).

1203 160 van den Brink, S. C. *et al.* Single-cell sequencing reveals dissociation-induced gene expression
1204 in tissue subpopulations. *Nat Methods* **14**, 935-936, doi:10.1038/nmeth.4437 (2017).

1205 161 van Velthoven, C. T. J., de Morree, A., Egner, I. M., Brett, J. O. & Rando, T. A. Transcriptional
1206 Profiling of Quiescent Muscle Stem Cells In Vivo. *Cell Rep* **21**, 1994-2004,
1207 doi:10.1016/j.celrep.2017.10.037 (2017).

1208 162 Medaglia, C. *et al.* Spatial reconstruction of immune niches by combining photoactivatable
1209 reporters and scRNA-seq. *Science* **358**, 1622-1626, doi:10.1126/science.aao4277 (2017).

1210 163 Vickovic, S. *et al.* High-definition spatial transcriptomics for in situ tissue profiling. *Nat*
1211 *Methods* **16**, 987-990, doi:10.1038/s41592-019-0548-y (2019).

1212 164 Rocha, B., Cillero-Pastor, B., Blanco, F. J. & Ruiz-Romero, C. MALDI mass spectrometry
1213 imaging in rheumatic diseases. *Biochim Biophys Acta Proteins Proteom* **1865**, 784-794,
1214 doi:10.1016/j.bbapap.2016.10.004 (2017).

1215 165 Chakraborty, T. *et al.* Light-sheet microscopy of cleared tissues with isotropic, subcellular
1216 resolution. *Nat Methods* **16**, 1109-1113, doi:10.1038/s41592-019-0615-4 (2019).

1217 166 Lavin, Y. Tissue-resident macrophage enhancer landscapes are shaped by the local
1218 microenvironment. *Cell* **159**, 1312-1326 (2014).

1219 167 Klein, K. *et al.* The epigenetic architecture at gene promoters determines cell type-specific
1220 LPS tolerance. *J Autoimmun* **83**, 122-133, doi:10.1016/j.jaut.2017.07.001 (2017).

1221 168 Ospelt, C. *et al.* Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients
1222 with early rheumatoid arthritis: toll-like receptor expression in early and longstanding
1223 arthritis. *Arthritis Rheum* **58**, 3684-3692, doi:10.1002/art.24140 (2008).

1224 169 Crowley, T. *et al.* Priming in response to pro-inflammatory cytokines is a feature of adult
1225 synovial but not dermal fibroblasts. *Arthritis Res Ther* **19**, 35, doi:10.1186/s13075-017-1248-
1226 6 (2017).

1227 170 Frank-Bertoncelj, M. *et al.* Epigenetically-driven anatomical diversity of synovial fibroblasts
1228 guides joint-specific fibroblast functions. *Nat Commun* **8**, 14852, doi:10.1038/ncomms14852
1229 (2017).

1230 171 Rinn, J. L., Bondre, C., Gladstone, H. B., Brown, P. O. & Chang, H. Y. Anatomic demarcation by
1231 positional variation in fibroblast gene expression programs. *PLoS genetics* **2**, e119,
1232 doi:10.1371/journal.pgen.0020119 (2006).

1233 172 Higuchi, Y. *et al.* Gastrointestinal Fibroblasts Have Specialized, Diverse Transcriptional
1234 Phenotypes: A Comprehensive Gene Expression Analysis of Human Fibroblasts. *PLoS One* **10**,
1235 e0129241, doi:10.1371/journal.pone.0129241 (2015).

1236 173 Hsueh, M. F., Onnerfjord, P., Bolognesi, M. P., Easley, M. E. & Kraus, V. B. Analysis of "old"
1237 proteins unmask dynamic gradient of cartilage turnover in human limbs. *Sci Adv* **5**,
1238 eaax3203, doi:10.1126/sciadv.aax3203 (2019).

1239 174 Quinn, T. M., Hauselmann, H. J., Shintani, N. & Hunziker, E. B. Cell and matrix morphology in
1240 articular cartilage from adult human knee and ankle joints suggests depth-associated
1241 adaptations to biomechanical and anatomical roles. *Osteoarthritis Cartilage* **21**, 1904-1912
1242 (2013).

1243 175 Treppo, S. *et al.* Comparison of biomechanical and biochemical properties of cartilage from
1244 human knee and ankle pairs. *J Orthop Res* **18**, 739-748, doi:10.1002/jor.1100180510 (2000).

- 176 Ai, R. *et al.* Joint-specific DNA methylation and transcriptome signatures in rheumatoid
arthritis identify distinct pathogenic processes. *Nat Commun* **7**, 11849,
doi:10.1038/ncomms11849 (2016).
- 177 den Hollander, W. *et al.* Knee and hip articular cartilage have distinct epigenomic landscapes:
implications for future cartilage regeneration approaches. *Ann Rheum Dis* **73**, 2208-2212,
doi:10.1136/annrheumdis-2014-205980 (2014).
- 178 Felsenthal, N. & Zelzer, E. Mechanical regulation of musculoskeletal system development.
Development **144**, 4271-4283, doi:10.1242/dev.151266 (2017).
- 179 Schroder, A. *et al.* Impact of Mechanical Load on the Expression Profile of Synovial
Fibroblasts from Patients with and without Osteoarthritis. *Int J Mol Sci* **20**,
doi:10.3390/ijms20030585 (2019).
- 180 Shimomura, K. *et al.* Cyclic compressive loading on 3D tissue of human synovial fibroblasts
upregulates prostaglandin E2 via COX-2 production without IL-1beta and TNF-alpha. *Bone
Joint Res* **3**, 280-288, doi:10.1302/2046-3758.39.2000287 (2014).

Acknowledgements

This report includes independent research supported by the National Institute for Health Research through the Birmingham Biomedical Research Center and Wellcome Trust Clinical Research Facility at University Hospitals Birmingham NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, our funding bodies or the Department of Health. Funding was also provided by the Versus Arthritis RACE Rheumatoid Arthritis Pathogenesis Centre of Excellence (grant 20298), a Versus Arthritis Programme grant to CDB (grant 19791) and a Versus Arthritis Senior Fellowship to KSM (grant 20003).

Competing interests

SG declares no competing interests. CO has received consultancy fees from Gilead Sciences Switzerland and funding from Novartis. CDB is a founder of MesTag Ltd and has received funding from MesTag. KSM is the founder and director of Nascent Ltd, and has received research funding from Nascent.

1278

1279

1280

Key points

1281

- All tissues are made up of cells surrounded by an extracellular matrix; this

1282

intricate, 3D molecular network is a both a key determinant of tissue

1283

architecture and cell behaviour.

1284

- The synovium is a complex anatomical tissue comprising many different cell

1285

(sub)populations, located in distinct subsynovial niches, where each are

1286

specialized to perform unique roles in synovial homeostasis.

1287

- In RA, infiltrating immune cells join tissue-resident cells; a quantum change

1288

accompanied by qualitative changes in cell phenotype that promote

1289

inflammation and tissue destruction, and suppress the resolution of

1290

inflammation.

1291

- The extracellular matrix plays a key role in dictating the organization of synovial

1292

cell ecosystems and in programming synovial cell specialization.

1293

- Changes in the synovial microenvironment start to occur early in the

1294

development of RA, and these aberrant extracellular cues shape pathogenic cell

1295

behaviour during the onset and progression of disease.

1296

- Analysing localized changes in the synovial microenvironment can improve

1297

disease classification and patient stratification, whilst targeting the extracellular

1298

matrix holds promise for the development of new strategies to treat and prevent

1299

RA.

1300

1301

Figure legends

Box 1 | Tissue specific extracellular matrix.

Tissues are made up of cells and extracellular matrix. The matrix consists of a 3D network of secreted molecules, coded for by genes that are collectively called the matrisome.

Matrisomal genes can be classified as: **1) core matrisomal genes**, including: *collagens*, *glycoproteins* (such as fibronectin, laminins, tenascins, thrombospondins), and *proteoglycans*, and **2) matrisome-associated genes** including *matrix-affiliated molecules* (such as mucins, lectins, syndecans, and galectins), *matrix regulators* (for example, crosslinking enzymes such as lysyl oxidases and transglutaminases, modifying enzymes such as kinases and sulfatases, proteases such as matrix metalloproteases (MMPs) and cathepsins, and protease inhibitors such as TIMPs and cystatins) and *soluble factors* (such as growth factors, Wnts, cytokines and chemokines). More than 1000 matrisomal genes exist.

Each tissue is formed by the assembly of a unique selection of these molecules into a complex extracellular network. These matrices confer different physical properties to tissues, and dictate both cellular organization and cellular behaviour within tissues.

In the human synovial joint, subchondral bone consists of a layer of compact cortical bone and underlying cancellous bone. A hard, calcified, type I collagen-rich matrix enables bones to provide anatomical support (**a**). The articular surface of bone in synovial joints consists of a smooth layer of hyaline articular cartilage, which provides compressive resistance in the joint. A matrix rich in type II collagen and proteoglycans confers the shock absorbing capabilities of cartilage (**b**). Tendons are the key functional anatomic bridges between muscle and bone. They focus the force of muscle into localized areas on the bone, the enthesis, and by splitting to form a number of insertions distribute the force of muscle contraction to different bones. A matrix comprising tightly packed parallel bundles of type I collagen fibrils confer tensile strength to tendons (**c**). The synovium is a thin mesenchymal membrane that encapsulates the joint space and provides boundary layer lubrication to ensure frictionless movement. A healthy synovium is composed of two distinct layers; an

intimal layer that is 20-40 micron thick, and a fibrous-areolar subintima that can be up to 5mm in thickness. The intima is composed of tissue resident macrophages and fibroblasts, supported by a discontinuous membrane made of types III, IV, V and VI collagen and laminin, which controls joint lubrication and nutrient exchange via the synovial fluid. The subintima contains blood and lymphatic vessels, as well as nerves and fibroblasts, in a looser collagenous extracellular matrix (d). Understanding tissue biology therefore requires understanding patterns of matrix gene expression, and how the resultant proteins are organized and modified to create distinct microenvironments.

Fig. 1 | The pannus is a key architectural feature of the inflamed synovium.

The region in the inflamed joint where hypertrophic synovium invades into adjacent cartilage and bone is called the pannus, where synovial cells and chondrocytes are closely juxtaposed. The left hand panel shows the overall architecture of the inflamed synovium, and the red boxed area in the right hand panel focuses in on the specific zone of synovial-cartilage interaction (a). In this relatively small anatomical zone, exquisitely site-specific patterns of gene expression are observed. Examples of pannus restricted biology include galectin-3 (b) and TLR2 (c) expression, both of which are upregulated specifically at these sites of invasion into underlying bone, and mediate localized synovial fibroblast activation and MMP synthesis, as well as localized chemokine synthesis that recruits infiltrating immune cells to the area.

Fig. 2 | Distinct fibroblast populations in the RA synovium inhabit distinct tissue niches.

Single cell transcriptional analysis reveals 5 different fibroblast populations in the inflamed mouse synovium (labelled F1-F5 here), three of which are conserved in human tissue.




Fig. 3 | Tissue microarchitecture in the healthy and RA joint.

Within sub-synovial niches, distinct combinations of matrix molecules define local tissue structure and function. The matrix confers physical properties to tissues, for example, at the articular surface proteoglycans and GAGs ensure frictionless joint articulation, a property diminished in RA as these molecules become degraded, creating pro-inflammatory matrix fragments (a). The synovial membrane forms a porous meshwork, comprising points of anchorage which organize lining layer cells into a cohesive network, together creating a barrier restricting cell movement, whose integrity is lost in RA (b). The matrix provides mechanical cues that directly control cell phenotype, these become altered during synovial hyperplasia and fibrosis, where changes in the organization of the fibrous interstitial matrix dictate stromal cell movement, whilst matrix stiffness impacts macrophage phenotype (c). As well as controlling the spatial positioning of cells by providing points of adhesion and migration barriers, the matrix also creates tracks which are permissive for cell migration, for example in and around the endothelial basement membrane. In RA, elevated expression of proteoglycans also pattern gradients of soluble factors around blood vessels, and serve as chemokine co-receptors, orchestrating enhanced cell infiltration via the perivascular niche (d). The matrix is a rich source of biochemical signals that are directly sensed by cell surface receptors to dictate cell behaviour, these signals may derive from complex multicomponent networks of extracellular molecules or fragments of matrix molecules generated during tissue remodelling. Both are exemplified in the pannus where ectopic matrix deposition provides a cell substrate permissive for immune cell activation and fibroblast spreading and invasion, whilst damaged matrix sustains signalling loops that perpetuate tissue destruction (f).

Fig. 4 | Shaping of joint specific cellular phenotypes.

1379 Positional memory in joint stroma cells can be modified at all stages of life. During
1380 embryonic development joint-specific pathways and stimulatory signals such as fetal
1381 movements work in concert with joint-specific HOX gene expression to shape the different
1382 joint regions¹⁷⁰. In early childhood, the transition to walking upright is associated with
1383 substantial adaptation of motor and biomechanical processes that shape gene expression in
1384 the tissues involved. Later in life, unphysiological load, trauma or other environmental
1385 factors such as infection and inflammation, e.g. rheumatoid arthritis can lead to joint-
1386 specific changes.

1387
1388
1389
1390

1391

Table 1 | Conserved cell populations in the RA joint.

Cell subset	Marker (human)	Marker (mouse)	Activation marker/effectors
Fibroblasts			
Lining layer	CD90- CD55+ PGR4+ F4	CD90- PGR4+ F5	RANKL:OPG ratio, CCL9, CLIC5, MMP1, MMP2, MMP3, MMP9, MMP13, HAS1, HTRA4, DNASE1L3
Immunomodulatory sublining layer	CD90+ CD34- HLA-DRA ^{hi} F2 CD90+ CD34- DKK+ F3	CD90+ CD34- F1	IL6, IL33, IL34, IFI30, Lif, CXCL9, CXCL12, CXCL13, CCL2, CCL19, CCL21
Perivascular sublining layer	CD90+ CD34+ F1	CD90+ CD34+ F3	
Macrophages			
Lining layer		CX3CR1+ CFSR1-	TREM2, VSIG4, AXL, MFGE8, JAM1, ZO-1, CLDN5, FAT4, VANGL2
Interstitial	NURP1+ CD11c- CD38- M2	CX3CR1- CFSR1+ MHCII+ AQP1+	MERTK, CTSK, HTRA1, GPNMB, ITGB5
	C1QA+ CD11c+ CD38+ M3	CX3CR1- CFSR1+ RELMA+	MRC1, CD163, MARCO
Monocyte-derived infiltrating	SPP1+ IFN-activated CD11c+ CCR2+ CD38+ M4 IL1b+ CD11c+ CCR2+ CD38+ M1	CCR2+ Ly6c2- ARG1+ CCR2+ Ly6c2- IL1b+	ARG1, IFI6, IFI44L, LY6E, SPP1 NR4A2, HBEGF, PLAUR, RGS2, IL1b, HTF3, CXCI2, EREG

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

Single cell transcriptional analysis of the human RA synovium has identified at least 18 different cell types, including fibroblast and macrophage subsets that are conserved in the inflamed murine synovium. Each cell subpopulation exhibits strikingly different localization within the joint and distinct functional specialization. Data summarised from references ^{27-30,33,35}.

Table 2 | How the tissue microenvironment can impact joint cell behaviour

Matrix	Effect and location	Reference
Physical properties and mechanical cues		
Hyaluronic acid	High levels in synovial fluid prevent friction	40
Lubricin	Distributed on the articular surface to lubricate the joint	41
Lining layer basement membrane	Maintains synovial integrity and immune privilege, by regulating and restricting, molecular and cellular exchange, that is lost in RA	4 43 33
Sub-intimal interstitial matrix	Controls matrix alignment and porosity, as well as tissue micromechanics, to regulate stromal cell adhesion and movement	45
	Dictates tissue stiffness which impacts macrophage polarization and activation	46
Spatial positioning		
Hyaluronic acid and lubricin	High levels in the synovial fluid prevent cell adhesion at the cartilage surface to facilitate unimpeded joint articulation	4
Fibronectin	Within the lining layer basement membrane promotes cell adhesion to create cohesive barrier function	49
	Ectopic expression in the RA pannus stabilizes cell invading machinery	50
	Up-regulation in the endothelial basement membrane in RA provides permissive tracks that support T cell infiltration	51,52
Soluble factor patterning and activity		
GAGs	High levels at the endothelial basement membrane in RA create chemokine gradients that enhance cell infiltration	54 55 56-58
HSPGs	Expression at the cell surface serves as a co-receptor for chemokines and growth factors, potentiating signalling	60 61 62 63
Direct signalling to cells		
Tenascin-C	Upregulation in the RA synovial sublining layer activates TLR4-mediated inflammation	70-72
Hyaluronic acid fragments	In RA synovial fluid, low molecular weight fragments activate TLR2-mediated inflammatory signalling	97
Osteopontin fragments	In RA synovial fluid, C-terminal fragments induce macrophage chemotaxis, and phosphorylated N-terminal fragments enhance macrophage spreading and activation	98 99,100
Damaged collagen	In the pannus, degradation of cartilage collagen increases localized MT1-MMP expression by synovial fibroblasts	95

1404
1405
1406
1407

Table 3 | Matrix targeting strategies in development for the treatment of RA

Approach	Mode of action	Development	Reference
Drug delivery			
Immunocytokine	Cytokine-antibody fusion protein DEKAVIL (F8-IL10): scFV of antibody F8 mediates delivery to inflamed joints via recognition of the EDA domain of fibronectin, where IL-10 exerts a localized anti-inflammatory effect.	Phase Ib	141
Chimeric antibodies	Anti-TNF antibodies fused to the heparin binding domain of PIGF-2, or to the collagen binding domain of decorin, are preferentially retained in the inflamed joint	Pre-clinical	143 144
Drug activity			
Chimeric cytokine receptors	Soluble TNFR fused to MMP cleavable adiponectin-derived cap creates controllable TNFR-TNF binding, activated at sites of high protease activity	In vitro	145
Inhibition of pathological processes			
Tissue destruction	Therapeutic monoclonal antibodies blocking the tissue degrading activity of specific proteases.	Phase 1b (MMP9) Pre-clinical (MT1-MMP)	148 149
Leukocyte infiltration	Decoy chemokines: signalling incompetent variants of CXCL8 with high HS affinity, or peptides comprising CXCL8 heparin binding domain, displace endogenous chemokine from tissue GAGs Decoy GAGs: soluble syndecan-3 competes for CXCL8 binding to endogenous syndecan at the endothelial lumen.	Pre-clinical Pre-clinical	150 151 152
Synovial inflammation	Therapeutic monoclonal antibodies that block osteopontin-fibronectin interactions, or that prevent activation of TLR4 by the fibrinogen like globe domain of tenascin-C	Pre-clinical	128,154

1408